Christopher B Granger

List of Publications by Year
in descending order

955 papers	122,738 citations	172 154 h-index	157 324 g-index
1031 all docs	1031 docs citations	1031 times ranked	66892 citing authors

#	Article	IF	Citations
1	Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2011, 365, 981-992.	13.9	7,537
2	Fourth universal definition of myocardial infarction (2018). European Heart Journal, 2019, 40, 237-269.	1.0	2,687
3	2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. Circulation, 2013, 127, e362-425.	1.6	2,639
4	2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2013, 61, e78-e140.	1.2	2,612
5	Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet, The, 2003, 362, 777-781.	6.3	2,584
6	A comprehensive 1000 Genomesâ€“based genome-wide association meta-analysis of coronary artery disease. Nature Genetics, 2015, 47, 1121-1130.	9.4	2,054
7	2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary. Circulation, 2013, 127, 529-555.	1.6	2,051
8	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet, The, 2003, 362, 767-771.	6.3	1,978
9	Predictors of Hospital Mortality in the Global Registry of Acute Coronary Events. Archives of Internal Medicine, 2003, 163, 2345.	4.3	1,856
10	Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, The, 2003, 362, 759-766.	6.3	1,752
11	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet, The, 2003, 362, 772-776.	6.3	1,623
12	A Common Variant on Chromosome 9p21 Affects the Risk of Myocardial Infarction. Science, 2007, 316, 1491-1493.	6.0	1,485
13	A Validated Prediction Model for All Forms of Acute Coronary Syndrome. JAMA - Journal of the American Medical Association, 2004, 291, 2727.	3.8	1,344
14	Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety. Chest, 2001, 119, 64S-94S.	0.4	1,275
15	Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurology, The, 2014, 13, 429-438.	4.9	1,268
16	Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ: British Medical Journal, 2006, 333, 1091.	2.4	1,236
17	2016 ACC/AHA Guideline FocusedÂUpdate on Duration of DualÂAntiplatelet Therapy in Patients With Coronary Artery Disease. Journal of the American College of Cardiology, 2016, 68, 1082-1115.	1.2	1,232
18	Dabigatran versus Warfarin in Patients with Mechanical Heart Valves. New England Journal of Medicine, 2013, 369, 1206-1214.	13.9	1,201

#	Article	IF	Citations
19	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet, The, 2018, 392, 1519-1529.	6.3	1,179
20	Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes. New England Journal of Medicine, 2006, 354, 1464-1476.	13.9	1,104
21	Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. New England Journal of Medicine, 2019, 381, 1909-1917.	13.9	1,100
22	2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Dis. Circulation, 2016, 134, e123-55.	1.6	1,069
23	Cardiac Troponin T Levels for Risk Stratification in Acute Myocardial Ischemia. New England Journal of Medicine, 1996, 335, 1333-1342.	13.9	1,042
24	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Journal of the American College of Cardiology, 2018, 72, e91-e220.	1.2	991
25	2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary. Journal of the American College of Cardiology, 2013, 61, 485-510.	1.2	905
26	Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet, The, 2008, 372, 1174-1183.	6.3	896
27	Relationship of Blood Transfusion and Clinical Outcomes in Patients With Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2004, 292, 1555.	3.8	894
28	Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. New England Journal of Medicine, 2019, 380, 1509-1524.	13.9	833
29	Effects of Fondaparinux on Mortality and Reinfarction in Patients With Acute ST-Segment Elevation Myocardial Infarction: The OASIS-6 Randomized Trial. JAMA - Journal of the American Medical Association, 2006, 295, 1519-1530.	3.8	830
30	Predictors of mortality and morbidity in patients with chronic heart failure. European Heart Journal, 2006, 27, 65-75.	1.0	822
31	Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure. Circulation, 2006, 113, 671-678.	1.6	817
32	Red Cell Distribution Width as a Novel Prognostic Marker in Heart Failure. Journal of the American College of Cardiology, 2007, 50, 40-47.	1.2	809
33	Early versus Delayed Invasive Intervention in Acute Coronary Syndromes. New England Journal of Medicine, 2009, 360, 2165-2175.	13.9	748
34	Decline in Rates of Death and Heart Failure in Acute Coronary Syndromes, 1999-2006. JAMA - Journal of the American Medical Association, 2007, 297, 1892.	3.8	744
35	Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet, The, 2010, 376, 1233-1243.	6.3	725
36	Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nature Genetics, 2009, 41, 342-347.	9.4	709

#	Article	IF	Citations
37	2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2016, 67, 1235-1250.	1.2	684
38	Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes. New England Journal of Medicine, 2010, 363, 930-942.	13.9	681
39	Heparin and Low-Molecular-Weight Heparin. Chest, 1998, 114, 489S-510S.	0.4	679
40	Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients. Circulation, 2005, 112, 3738-3744.	1.6	678
41	The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nature Genetics, 2008, 40, 217-224.	9.4	668
42	The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. European Heart Journal, 2012, 33, 1750-1757.	1.0	652
43	Risk Factors, Angiographic Patterns, and Outcomes in Patients With Ventricular Septal Defect Complicating Acute Myocardial Infarction. Circulation, 2000, 101, 27-32.	1.6	635
44	Fundamentals of Clinical Trials. , 2015, , .		603
45	Impact of Bleeding Severity on Clinical Outcomes Among Patients With Acute Coronary Syndromes. American Journal of Cardiology, 2005, 96, 1200-1206.	0.7	598
46	Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. New England Journal of Medicine, 2017, 376, 1933-1942.	13.9	593
47	Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. New England Journal of Medicine, 2019, 380, 1906-1917.	13.9	568
48	Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal, 2008, 29, 1377-1385.	1.0	549
49	Dronedarone in High-Risk Permanent Atrial Fibrillation. New England Journal of Medicine, 2011, 365, 2268-2276.	13.9	547
50	Relationship Between Delay in Performing Direct Coronary Angioplasty and Early Clinical Outcome in Patients With Acute Myocardial Infarction. Circulation, 1999, 100, 14-20.	1.6	532
51	Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure. Circulation, 2007, 116, 1482-1487.	1.6	528
52	Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction. Journal of the American College of Cardiology, 1999, 34, 1711-1720.	1.2	510
53	Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction. Journal of the American College of Cardiology, 2006, 47, 1997-2004.	1.2	507
54	Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. European Heart Journal, 2012, 33, 2821-2830.	1.0	491

#	Article	IF	Citations
55	Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. European Heart Journal, 2011, 32, 2781-2789.	1.0	487
56	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Circulation, 2018, 138, e272-e391.	1.6	468
57	Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease. New England Journal of Medicine, 2014, 370, 1702-1711.	13.9	467
58	Myonecrosis After Revascularization Procedures. Journal of the American College of Cardiology, 1998, 31, 241-251.	1.2	459
59	Prognostic Value of the Admission Electrocardiogram in Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 1999, 281, 707.	3.8	451
60	2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary. Heart Rhythm, 2018, 15, e190-e252.	0.3	448
61	Relationship Between Infarct Size and Outcomes Following Primary PCI. Journal of the American College of Cardiology, 2016, 67, 1674-1683.	1.2	444
62	Sex Differences in Mortality Following Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2009, 302, 874.	3.8	440
63	Prognostic Implications of Abnormalities in Renal Function in Patients With Acute Coronary Syndromes. Circulation, 2002, 106, 974-980.	1.6	432
64	Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet, The, 2005, 366, 2005-2011.	6.3	410
65	Apixaban for Reduction In Stroke and Other ThromboembоLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale. American Heart Journal, 2010, 159, 331-339.	1.2	407
66	2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. Circulation, 2016, 133, 1135-1147.	1.6	403
67	Influence of Diabetes Mellitus on Clinical Outcome in the Thrombolytic Era of Acute Myocardial Infarction fn1fn1The GUSTO-I study was supported by a combined grant from Bayer, New York, New York; CIBA-Corning, Medfield, Massachusetts; Genetech, South San Francisco, California; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France.. Journal of the American College of Cardiology, 1997, 30, 171-179.	1.2	392
68	The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet, The, 2016, 387, 2302-2311.	6.3	389
69	Atrial Fibrillation in the Setting of Acute Myocardial Infarction: The GUSTO-I Experience fn1fn1This study was funded by grants from Genentech, South San Francisco, California; Bayer Corporation, New York, New York; CIBA-Corning, Medfield, Massachusetts; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France.. Journal of the American College of Cardiology, 1997, 30, 406-413.	1.2	384
70	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary. Journal of the American College of Cardiology, 2018, 72, 1677-1749.	1.2	382
71	Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2007, 297, 43.	3.8	368
72	2013 ACCF/AHA Guideline for the Management of STâ€Elevation Myocardial Infarction: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Catheterization and Cardiovascular Interventions, 2013, 82, E1-27.	0.7	368

#	Article	IF	Citations
73	Efficacy and Safety of Tenecteplase in Combination With the Low-Molecular-Weight Heparin Enoxaparin or Unfractionated Heparin in the Prehospital Setting. Circulation, 2003, 108, 135-142.	1.6	363
74	Declining Risk of Sudden Death in Heart Failure. New England Journal of Medicine, 2017, 377, 41-51.	13.9	355
75	Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction. Circulation, 2004, 110, 2618-2626.	1.6	347
76	Medication adherence: A call for action. American Heart Journal, 2011, 162, 412-424.	1.2	340
77	The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. European Heart Journal, 2016, 37, 1582-1590.	1.0	329
78	Body Mass Index and Prognosis in Patients With Chronic Heart Failure. Circulation, 2007, 116, 627-636.	1.6	328
79	Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. European Journal of Heart Failure, 2009, 11, 170-177.	2.9	326
80	Use of Medical Resources and Quality of Life after Acute Myocardial Infarction in Canada and the United States. New England Journal of Medicine, 1994, 331, 1130-1135.	13.9	322
81	Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction. Circulation, 2003, 108, 1184-1190.	1.6	315
82	Association of Bystander and First-Responder Intervention With Survival After Out-of-Hospital Cardiac Arrest in North Carolina, 2010-2013. JAMA - Journal of the American Medical Association, 2015, 314, 255.	3.8	315
83	Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study. American Heart Journal, 2019, 207, 66-75.	1.2	311
84	Implementation of a Statewide System for Coronary Reperfusion for ST-Segment Elevation Myocardial Infarction. JAMA - Journal of the American Medical Association, 2007, 298, 2371.	3.8	309
85	Major Bleeding in Patients With AtrialÂFibrillation Receiving Apixaban or Warfarin. Journal of the American College of Cardiology, 2014, 63, 2141-2147.	1.2	308
86	Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. European Heart Journal, 2014, 35, 1864-1872.	1.0	303
87	Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19. JAMA - Journal of the American Medical Association, 2021, 325, 254.	3.8	299
88	Heart failure with midâ€range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure, 2018, 20, 1230-1239.	2.9	295
89	A Comparison of the Clinical Impact of Bleeding Measured by Two Different Classifications Among Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2006, 47, 809-816.	1.2	283
90	Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. American Heart Journal, 2006, 152, 86-92.	1.2	275

#	Article	IF	Citations
91	Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. Journal of the American College of Cardiology, 1993, 21, 920-925.	1.2	273
92	Extent of, and factors associated with, delay to hospital presentation in patients with acute coronary disease (the GRACE registry). American Journal of Cardiology, 2002, 89, 791-796.	0.7	271
93	Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease. American Heart Journal, 2012, 163, 844-850.e1.	1.2	271
94	Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials. European Heart Journal, 2017, 38, 3502-3510.	1.0	271
95	Extent, Location, and Clinical Significance of Nonâ€"Infarct-Related Coronary Artery Disease Among Patients With ST-Elevation Myocardial Infarction. JAMA - Journal of the American Medical Association, 2014, 312, 2019.	3.8	263
96	2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Heart Rhythm, 2018, 15, e73-e189.	0.3	262
97	Value of Serial Troponin T Measures for Early and Late Risk Stratification in Patients With Acute Coronary Syndromes. Circulation, 1998, 98, 1853-1859.	1.6	259
98	Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. American Heart Journal, 2017, 189, 137-145.	1.2	258
99	Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. European Heart Journal, 2007, 28, 1193-1204.	1.0	253
100	Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2007, 50, 1742-1751.	1.2	253
101	Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurology, The, 2012, 11, 503-511.	4.9	252
102	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary. Circulation, 2018, 138, e210-e271.	1.6	250
103	2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. Journal of Thoracic and Cardiovascular Surgery, 2016, 152, 1243-1275.	0.4	249
104	Biomarkers in atrial fibrillation: a clinical review. European Heart Journal, 2013, 34, 1475-1480.	1.0	246
105	Stroke After Thrombolysis. Circulation, 1995, 92, 2811-2818.	1.6	244
106	Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients With Atrial Fibrillation. Circulation, 2014, 130, 1847-1858.	1.6	243
107	Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients. Circulation, 2004, 110, 2180-2183.	1.6	241
108	Evolution of Critical Care Cardiology: Transformation of the Cardiovascular Intensive Care Unit and the Emerging Need for New Medical Staffing and Training Models. Circulation, 2012, 126, 1408-1428.	1.6	240

#	Article	IF	Citations
109	Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet, The, 2009, 374, 543-550.	6.3	239
110	Incidence of and Outcomes Associated With Ventricular Tachycardia or Fibrillation in Patients Undergoing Primary Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2009, 301, 1779.	3.8	238
111	Post-Myocardial Infarction Heart Failure. JACC: Heart Failure, 2018, 6, 179-186.	1.9	237
112	Registry-based randomized clinical trialsâ€"a new clinical trial paradigm. Nature Reviews Cardiology, 2015, 12, 312-316.	6.1	236
113	Acute Coronary Syndromes in the GUSTO-IIb Trial. Circulation, 1998, 98, 1860-1868.	1.6	235
114	Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. Journal of the American College of Cardiology, 2001, 37, 9-18.	1.2	235
115	Sex Differences in Clinical Characteristics and Prognosis in a Broad Spectrum of Patients With Heart Failure. Circulation, 2007, 115, 3111-3120.	1.6	235
116	Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go. European Heart Journal, 2008, 29, 609-617.	1.0	233
117	Activated Partial Thromboplastin Time and Outcome After Thrombolytic Therapy for Acute Myocardial Infarction. Circulation, 1996, 93, 870-878.	1.6	232
118	Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patients With Heart Failure. Circulation, 2006, 113, 986-994.	1.6	229
119	Efficacy and Safety of Apixaban in Patients After Cardioversion for Atrial Fibrillation. Journal of the American College of Cardiology, 2014, 63, 1082-1087.	1.2	228
120	Cardiogenic Shock in Patients With Acute Ischemic Syndromes With and Without ST-Segment Elevation. Circulation, 1999, 100, 2067-2073.	1.6	225
121	From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes The Global Registry of Acute Coronary Events (GRACE). European Heart Journal, 2003, 24, 1414-1424.	1.0	225
122	Age and Outcome With Contemporary Thrombolytic Therapy. Circulation, 1996, 94, 1826-1833.	1.6	224
123	Comparison of the ABC/2 Estimation Technique to Computer-Assisted Volumetric Analysis of Intraparenchymal and Subdural Hematomas Complicating the GUSTO-1 Trial. Stroke, 1998, 29, 1799-1801.	1.0	213
124	Does Comorbidity Account for the Excess Mortality in Patients With Major Bleeding in Acute Myocardial Infarction?. Circulation, 2007, 116, 2793-2801.	1.6	213
125	Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart Failure. Circulation, 2005, 112, 48-53.	1.6	211
126	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. Circulation, 2018, 138, 527-536.	1.6	211

#	Article	IF	Citations
127	Mechanical Complications After Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction (from APEX-AMI). American Journal of Cardiology, 2010, 105, 59-63.	0.7	208
128	Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease. Circulation, 2015, 132, 624-632.	1.6	203
129	Intracoronary KAI-9803 as an Adjunct to Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction. Circulation, 2008, 117, 886-896.	1.6	200
130	Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. European Heart Journal, 2010, 31, 1701-1707.	1.0	199
131	Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. American Journal of Medicine, 2004, 117, 73-81.	0.6	198
132	Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. JAMA Cardiology, 2019, 4, 747.	3.0	198
133	Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation. Circulation, 2013, 127, 2166-2176.	1.6	196
134	Continuous 12-lead ST-segment recovery analysis in the TAMI 7 study. Performance of a noninvasive method for real-time detection of failed myocardial reperfusion.. Circulation, 1993, 88, 437-446.	1.6	195
135	The â€˜obesity paradoxâ€™ in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in) Tj ETQq1 1 0.784314 rgBT 2869-2878.	1.0	194
136	Incidence and Predictors of Bleeding After Contemporary Thrombolytic Therapy for Myocardial Infarction. Circulation, 1997, 95, 2508-2516.	1.6	194
137	N-Terminal Proâ€“B-Type Natriuretic Peptide for RiskÂAssessment in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2013, 61, 2274-2284.	1.2	191
138	Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. European Journal of Heart Failure, 2007, 9, 83-91.	2.9	188
139	Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to <scp>CHARM</scp>â€Preserved. European Journal of Heart Failure, 2014, 16, 33-40.	2.9	186
140	Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. Journal of the American College of Cardiology, 2017, 70, 1689-1700.	1.2	186
141	Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events. European Heart Journal, 2010, 31, 1449-1456.	1.0	185
142	Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm. Nature Genetics, 2010, 42, 692-697.	9.4	181
143	Association of Statin Therapy with Outcomes of Acute Coronary Syndromes: The GRACE Study. Annals of Internal Medicine, 2004, 140, 857.	2.0	178
144	Rebound Increase in Thrombin Generation and Activity After Cessation of Intravenous Heparin in Patients With Acute Coronary Syndromes. Circulation, 1995, 91, 1929-1935.	1.6	177

#	Article	IF	Citations
145	Effect of Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Fibrinolysis in Acute Myocardial Infarction. Circulation, 2003, 108, 1176-1183.	1.6	176
146	Use of Intraaortic Balloon Counterpulsation in Patients Presenting With Cardiogenic Shock: Observations From the GUSTO-I Study fn1fn1This study was funded by grants from Bayer, New York, New York; CIBA-Corning, Medfield, Massachusetts; Genentech, South San Francisco, California; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France.. Journal of the American College of Cardiology, 1997, 30, 708-715.	1.2	175
147	Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet, The, 2012, 380, 1749-1758.	6.3	175
148	Coronary Artery Disease in PatientsÂâ‰¥80 Years of Age. Journal of the American College of Cardiology, 2018, 71, 2015-2040.	1.2	175
149	Rapid ventricular filling in left ventricular hypertrophy: I. Physiologic hypertrophy. Journal of the American College of Cardiology, 1985, 5, 862-868.	1.2	169
150	RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. European Heart Journal, 2011, 32, 2541-2554.	1.0	165
151	Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal, 2008, 29, 2641-2650.	1.0	164
152	A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The Randomized, phase II study to Evaluate the sAfety and pharmacokinetics of oraL dabIGatran etexilate in patients after heart valve replacemeNt (RE-ALIGN). American Heart Journal, 2012, 163, 931-937.e1.	1.2	164
153	Continuously updated 12-lead ST-segment recovery analysis for myocardial infarct artery patency assessment and its correlation with multiple simultaneous early angiographic observations. American Journal of Cardiology, 1993, 71, 145-151.	0.7	162
154	Prognostic significance of the change in glucose level in the first 24â€…h after acute myocardial infarction: results from the CARDINAL study. European Heart Journal, 2006, 27, 1289-1297.	1.0	161
155	Risk Stratification and Therapeutic Decision Making in Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2000, 284, 876.	3.8	160
156	Prognostic Significance of the Initial Electrocardiogram in Patients With Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 1998, 279, 387.	3.8	158
157	Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb Study. European Heart Journal, 2000, 21, 1750-1758.	1.0	156
158	Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. European Heart Journal, 2013, 34, 2464-2471.	1.0	154
159	A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial. Lancet, The, 2017, 390, 1737-1746.	6.3	154
160	Incidence and Predictors of Hyperkalemia in Patients With Heart Failure. Journal of the American College of Cardiology, 2007, 50, 1959-1966.	1.2	153
161	Sensible approaches for reducing clinical trial costs. Clinical Trials, 2008, 5, 75-84.	0.7	153
162	Gene Expression Patterns in Peripheral Blood Correlate with the Extent of Coronary Artery Disease. PLoS ONE, 2009, 4, e7037.	1.1	153

#	Article	IF	Citations
163	A Genomewide Scan for Early-Onset Coronary Artery Disease in 438 Families: The GENECARD Study. American Journal of Human Genetics, 2004, 75, 436-447.	2.6	152
164	Evolution of the coronary care unit: Clinical characteristics and temporal trends in healthcare delivery and outcomes*. Critical Care Medicine, 2010, 38, 375-381.	0.4	151
165	Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. European Heart Journal, 2008, 30, 655-661.	1.0	149
166	Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood, 2014, 124, 3692-3698.	0.6	149
167	Design of Randomized, Double-Blind, Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate vs. Acetylsalicylic Acid in Patients with Embolic Stroke of Undetermined Source (Re-Spect Esus). International Journal of Stroke, 2015, 10, 1309-1312.	2.9	147
168	Digoxin and Mortality in Patients WithÂAtrial Fibrillation. Journal of the American College of Cardiology, 2018, 71, 1063-1074.	1.2	147
169	Association of the PHACTR1/EDN1 Genetic Locus With Spontaneous Coronary Artery Dissection. Journal of the American College of Cardiology, 2019, 73, 58-66.	1.2	147
170	ST-Segment Recovery and Outcome After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. Circulation, 2008, 118, 1335-1346.	1.6	146
171	Association of Heart Rate and Outcomes in a Broad Spectrum of Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 2012, 59, 1785-1795.	1.2	146
172	Thrombolytic Therapy for Acute Myocardial Infarction. Drugs, 1992, 44, 293-325.	4.9	145
173	Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb11Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network (PARAGON-A); Global Use of Strategies To Open occluded arteries in acute coronary syndromes (GUSTO-IIb).. Journal of the American College of Cardiology, 2001, 38, 64-71.	1.2	145
174	Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation. American Journal of Cardiology, 2003, 92, 1031-1036.	0.7	145
175	Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. European Heart Journal, 2015, 36, 1264-1272.	1.0	144
176	Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. JAMA - Journal of the American Medical Association, 1995, 273, 1586-1591.	3.8	144
177	Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. American Heart Journal, 2011, 162, 900-906.	1.2	143
178	Design and rationale of CURRENT-OASIS 7: A randomized, 2 Ã— 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and nonâ€“ST-elevation acute coronary syndromes managed with an early invasive strategy. American Heart Journal, 2008, 156, 1080-1088.e1.	1.2	140
179	High heritability of metabolomic profiles in families burdened with premature cardiovascular disease. Molecular Systems Biology, 2009, 5, 258.	3.2	140
180	Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. European Heart Journal, 2014, 35, 224-232.	1.0	140

#	Article	IF	Citations
181	Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Journal of the American College of Cardiology, 1998, 32, 634-640.	1.2	139
182	Prognostic implications of TIMI flow grade in the infarct related artery compared with continuous 12-lead ST-segment resolution analysis. Journal of the American College of Cardiology, 2000, 35, 666-672.	1.2	139
183	Sustained Ventricular Arrhythmias Among Patients With Acute Coronary Syndromes With No ST-Segment Elevation. Circulation, 2002, 106, 309-312.	1.6	139
184	Demographics, Care Patterns, and Outcomes of Patients Admitted to Cardiac Intensive Care Units. JAMA Cardiology, 2019, 4, 928.	3.0	139
185	Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time. JAMA Cardiology, 2016, 1, 451.	3.0	137
186	Left Ventricular Systolic Dysfunction, Heart Failure, and the Risk of Stroke and Systemic Embolism in Patients With Atrial Fibrillation. Circulation: Heart Failure, 2013, 6, 451-460.	1.6	136
187	Acute Myocardial Infarction and Complete Bundle Branch Block at Hospital Admission: Clinical Characteristics and Outcome in the Thrombolytic Era fn1fn1This study was supported by grants from Bayer Corporation, New York, New York; Genentech, Inc., South San Francisco, California; CIBA-Corning, Medford, Massachusetts; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France.. Journal of the American College of Cardiology, 1998, 31, 105-110.	1.2	135
188	Risk factors and outcomes in patients with ventricular septal defects (VSD) complicating acute MI. Journal of the American College of Cardiology, 1996, 27, 67-68.	1.2	133
189	High-Sensitivity Troponin T and Risk Stratification in Patients With Atrial Fibrillation During Treatment With Apixaban or Warfarin. Journal of the American College of Cardiology, 2014, 63, 52-61.	1.2	133
190	Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. American Journal of Cardiology, 1999, 84, 1281-1286.	0.7	132
191	Reperfusion Strategies in Acute ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2007, 50, 917-929.	1.2	132
192	Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. European Heart Journal, 2009, 30, 2019-2028.	1.0	130
193	Angiotensin Receptorâ€“Neprilysin Inhibition in Acute Myocardial Infarction. New England Journal of Medicine, 2021, 385, 1845-1855.	13.9	130
194	Management of Antithrombotic Therapy in Atrial Fibrillation Patients UndergoingÂPCI. Journal of the American College of Cardiology, 2019, 74, 83-99.	1.2	126
195	Acute Cardiovascular Care Association position statement for the diagnosis and treatment of patients with acute myocardial infarction complicated by cardiogenic shock: A document of the Acute Cardiovascular Care Association of the European Society of Cardiology. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 183-197.	0.4	126
196	A Genome-Wide Association Study for Coronary Artery Disease Identifies a Novel Susceptibility Locus in the Major Histocompatibility Complex. Circulation: Cardiovascular Genetics, 2012, 5, 217-225.	5.1	125
197	Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. Lancet, The, 2014, 384, 1187-1195.	6.3	123
198	Influence of Previous Heart Failure Hospitalization on Cardiovascular Events in Patients With Reduced and Preserved Ejection Fraction. Circulation: Heart Failure, 2014, 7, 590-595.	1.6	123

#	Article	IF	Citations
199	Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ, The, 2016, 353, i2868.	3.0	123
200	Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. European Heart Journal, 2005, 26, 1964-1970.	1.0	120
201	Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial. American Journal of Medicine, 2017, 130, 1440-1448.e1.	0.6	120
202	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. Circulation, 2021, 143, 583-596.	1.6	119
203	Thrombolysis-Related Intracranial Hemorrhage. Stroke, 1998, 29, 563-569.	1.0	118
204	Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial. American Heart Journal, 2020, 226, 49-59.	1.2	118
205	Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. Circulation, 2022, 145, 242-255.	1.6	118
206	Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents. A comparison of TNK-tPA and rt-PA. European Heart Journal, 2001, 22, 2253-2261.	1.0	117
207	Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. Lancet, The, 2015, 386, 303-310.	6.3	117
208	Effect of Long-term Continuous Cardiac Monitoring vs Usual Care on Detection of Atrial Fibrillation in Patients With Stroke Attributed to Large- or Small-Vessel Disease. JAMA - Journal of the American Medical Association, 2021, 325, 2169.	3.8	114
209	Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. American Heart Journal, 2000, 139, 609-617.	1.2	113
210	Randomized, Blinded Trial Comparing Fondaparinux With Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention. Circulation, 2005, 111, 1390-1397.	1.6	113
211	Do we need to adjudicate major clinical events?. Clinical Trials, 2008, 5, 56-60.	0.7	111
212	Aborted myocardial infarction in patients with ST-segment elevation. Journal of the American College of Cardiology, 2004, 44, 38-43.	1.2	110
213	Peakwide Mapping on Chromosome 3q13 Identifies the Kalirin Gene as a Novel Candidate Gene for Coronary Artery Disease. American Journal of Human Genetics, 2007, 80, 650-663.	2.6	110
214	Systems of Care for ST-Segmentâ€"Elevation Myocardial Infarction: A Report From the American Heart Associationâ€™s Mission: Lifeline. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 423-428.	0.9	110
215	High-Sensitivity Troponin I for Risk Assessment in Patients With Atrial Fibrillation. Circulation, 2014, 129, 625-634.	1.6	110
216	Validation of the association between a branched chain amino acid metabolite profile and extremes of coronary artery disease in patients referred for cardiac catheterization. Atherosclerosis, 2014, 232, 191-196.	0.4	109

#	Article	IF	Citations
217	In-Hospital Revascularization and One-Year Outcome of Acute Coronary Syndrome Patients Stratified by the GRACE Risk Score. American Journal of Cardiology, 2005, 96, 913-916.	0.7	108
218	Rationale for establishing regional ST-elevation myocardial infarction receiving center (SRC) networks. American Heart Journal, 2006, 152, 661-667.	1.2	107
219	Adherence to medication according to sex and age in the CHARM programme. European Journal of Heart Failure, 2009, 11, 1092-1098.	2.9	107
220	Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. American Heart Journal, 1999, 137, 792-798.	1.2	106
221	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. European Heart Journal, 2017, 38, ehw069.	1.0	106
222	Practice patterns, outcomes, and end-organ dysfunction for patients with acute severe hypertension: The Studying the Treatment of Acute hyperTension (STAT) Registry. American Heart Journal, 2009, 158, 599-606.e1.	1.2	105
223	International Variation in and Factors Associated With Hospital Readmission After Myocardial Infarction. JAMA - Journal of the American Medical Association, 2012, 307, 66.	3.8	105
224	Differences between men and women in the management of unstable angina pectoris (the Guarantee) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.7	104
225	Randomized Clinical Trials â€" Removing Unnecessary Obstacles. New England Journal of Medicine, 2013, 369, 1061-1065.	13.9	103
226	Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)â€"Added trial. American Heart Journal, 2006, 151, 985-991.	1.2	102
227	Time to Treatment Influences the Impact of ST-Segment Resolution on One-Year Prognosis. Circulation, 2001, 104, 2653-2659.	1.6	101
228	The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: Lessons from the Global Registry of Acute Coronary Events (GRACE). American Heart Journal, 2006, 151, 654-660.	1.2	101
229	Emergency Department Bypass for ST-Segmentâ€"Elevation Myocardial Infarction Patients Identified With a Prehospital Electrocardiogram. Circulation, 2013, 128, 352-359.	1.6	101
230	Impact of Regionalization of ST-Segmentâ€"Elevation Myocardial Infarction Care on Treatment Times and Outcomes for Emergency Medical Servicesâ€"Transported Patients Presenting to Hospitals With Percutaneous Coronary Intervention. Circulation, 2018, 137, 376-387.	1.6	101
231	The Impact of a Statewide Pre-Hospital STEMI Strategy to Bypass Hospitals Without Percutaneous Coronary Intervention Capability on Treatment Times. Circulation, 2013, 127, 604-612.	1.6	99
232	Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST- and Nonâ€"ST-Segment Elevation Acute Coronary Syndromes. Circulation, 2008, 118, 2038-2046.	1.6	98
233	Temporal Differences in Out-of-Hospital Cardiac Arrest Incidence and Survival. Circulation, 2013, 128, 2595-2602.	1.6	98
234	Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: Lessons from 4 international fibrinolytic therapy trials. American Heart Journal, 2003, 145, 73-79.	1.2	97

#	Article	IF	Citations
235	Clopidogrel use and bleeding after coronary artery bypass graft surgery. American Heart Journal, 2008, 156, 886-892.	1.2	97
236	Age-Related Characteristics and Outcomes of Patients With HeartÂFailure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2019, 74, 601-612.	1.2	97
237	Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. European Heart Journal, 1999, 20, 1182-1190.	1.0	96
238	Cognitive Function and Anticoagulation Control in Patients With Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2010, 3, 277-283.	0.9	96
239	Medication performance measures and mortality following acute coronary syndromes. American Journal of Medicine, 2005, 118, 858-865.	0.6	95
240	The role of bystanders, first responders, and emergency medical service providers in timely defibrillation and related outcomes after out-of-hospital cardiac arrest: Results from a statewide registry. Resuscitation, 2015, 96, 303-309.	1.3	95
241	Biomarker-Based Risk Model to PredictÂCardiovascular Mortality in PatientsÂWithÂStableÂCoronaryÂDisease. Journal of the American College of Cardiology, 2017, 70, 813-826.	1.2	95
242	Early Reinfarction After Fibrinolysis. Circulation, 2001, 104, 1229-1235.	1.6	94
243	Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy. American Heart Journal, 2005, 149, 670-674.	1.2	94
244	Novel oral anticoagulants in gastroenterology practice. Gastrointestinal Endoscopy, 2013, 78, 227-239.	0.5	94
245	Post-Hospital Outcomes of PatientsÂWithÂAcute Myocardial Infarction WithÂCardiogenic Shock. Journal of the American College of Cardiology, 2016, 67, 739-747.	1.2	93
246	Randomized Comparison of Direct Thrombin Inhibition Versus Heparin in Conjunction With Fibrinolytic Therapy for Acute Myocardial Infarction: Results From the GUSTO-IIb Trial. Journal of the American College of Cardiology, 1998, 31, 1493-1498.	1.2	92
247	Practical Management of Anticoagulation in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2015, 65, 1340-1360.	1.2	92
248	A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 222	1.0	92
249	Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. European Heart Journal, 2020, 41, 4037-4046.	1.0	90
250	Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: The Early Rapid ReversAl of Platelet ThromboSis with Intravenous Elinogrel before PCI to Optimize REperfusion in Acute Myocardial Infarction (ERASE MI) pilot trial. American Heart Journal, 2009, 158, 998-1004.e1.	1.2	89
251	Incidence and Prognostic Significance of Thrombocytopenia in Patients Treated With Prolonged Heparin Therapy. Archives of Internal Medicine, 2008, 168, 94.	4.3	87
252	Neuropeptide Y Gene Polymorphisms Confer Risk of Early-Onset Atherosclerosis. PLoS Genetics, 2009, 5, e1000318.	1.5	87

#	Article	IF	Citations
253	Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial. American Journal of Medicine, 2018, 131, 269-275.e2.	0.6	87
254	Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. Circulation, 2020, 141, 1384-1392.	1.6	87
255	Association of Elevated Fasting Glucose With Increased Short-term and 6-Month Mortality in ST-Segment Elevation and Nonâ€“ST-Segment Elevation Acute Coronary Syndromes. Archives of Internal Medicine, 2009, 169, 402.	4.3	86
256	2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with STâ€elevation myocardial Infarction: An update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of STâ€elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Catheterization and Cardiovascular Interventions, 2016, 87, 1001-1019.	0.7	85
257	Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. Blood, 2017, 129, 2980-2987.	0.6	85
258	Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. American Journal of Cardiology, 1996, 77, 551-556.	0.7	84
259	Lack of Association Between the Trp719Arg Polymorphism in Kinesin-Like Protein-6 and Coronary Artery Disease in 19 Case-Control Studies. Journal of the American College of Cardiology, 2010, 56, 1552-1563.	1.2	84
260	Clinical Characteristics and Outcomes of Young and Very Young Adults With Heart Failure. Journal of the American College of Cardiology, 2013, 62, 1845-1854.	1.2	84
261	Amiodarone, Anticoagulation, andÂClinicalÂEvents in Patients WithÂAtrialÂFibrillation. Journal of the American College of Cardiology, 2014, 64, 1541-1550.	1.2	84
262	Stroke risk assessment in atrial fibrillation: risk factors and markers of atrial myopathy. Nature Reviews Cardiology, 2016, 13, 549-559.	6.1	84
263	Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention. Circulation, 2020, 141, 1618-1627.	1.6	84
264	Diabetic Retinopathy Should Not Be a Contraindication to Thrombolytic Therapy for Acute Myocardial Infarction: Review of Ocular Hemorrhage Incidence and Location in the GUSTO-I Trial fn1fn1This study was supported by Bayer, New York, New York; CIBA-Corning, Medfield, Massachusetts; Genentech, South San Francisco, California; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France.. Journal of the American College of Cardiology, 1997, 30, 1606-1610.	1.2	83
265	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2016, 9, .	1.4	83
266	GATA2 Is Associated with Familial Early-Onset Coronary Artery Disease. PLoS Genetics, 2006, 2, e139.	1.5	82
267	Reperfusion Strategies in Acute Coronary Syndromes. Circulation Research, 2014, 114, 1918-1928.	2.0	82
268	Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. European Heart Journal, 2010, 31, 50-58.	1.0	81
269	Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-up. American Journal of Medicine, 2015, 128, 766-775.	0.6	81
270	Regional Systems of Care Demonstration Project. Circulation, 2016, 134, 365-374.	1.6	81

#	Article	IF	Citations
271	Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine. JAMA Cardiology, 2016, 1, 673.	3.0	81
272	A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. American Journal of Cardiology, 1994, 74, 1220-1228.	0.7	80
273	Identification of Patients With Stable Chest Pain Deriving Minimal Value From Noninvasive Testing. JAMA Cardiology, 2017, 2, 400.	3.0	80
274	Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial. Clinical Cardiology, 2019, 42, 568-571.	0.7	80
275	Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. Circulation, 2020, 141, 781-783.	1.6	80
276	Newer Oral Anticoagulants Should Be Used as First-Line Agents to Prevent Thromboembolism in Patients With Atrial Fibrillation and Risk Factors for Stroke or Thromboembolism. Circulation, 2012, 125, 159-164.	1.6	79
277	Out-of-Hospital Cardiac Arrest Resuscitation Systems of Care: A Scientific Statement From the American Heart Association. Circulation, 2018, 137, e645-e660.	1.6	79
278	Prognostic significance of precordial ST segment depression during inferior myocardial infarction in the thrombolytic era: Results in 16,521 patients. Journal of the American College of Cardiology, 1996, 28, 305-312.	1.2	78
279	Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study. Current Controlled Trials in Cardiovascular Medicine, 2001, 2, 187.	1.5	78
280	Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction*. Critical Care Medicine, 2011, 39, 78-83.	0.4	78
281	Expansion of a Regional ST-Segmentâ€“Elevation Myocardial Infarction System to an Entire State. Circulation, 2012, 126, 189-195.	1.6	78
282	Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. Circulation, 2019, 139, 2292-2300.	1.6	78
283	Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2019, 12, e006539.	1.6	78
284	Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-IIb angioplasty substudy. Journal of the American College of Cardiology, 2000, 35, 1502-1512.	1.2	77
285	Validity of a risk-prediction tool for hospital mortality: The Global Registry of Acute Coronary Events. American Heart Journal, 2009, 157, 1097-1105.	1.2	77
286	Noninvasive assessment of speed and stability of infarct-related artery reperfusion: Results of the GUSTO ST segment monitoring study. Journal of the American College of Cardiology, 1995, 25, 1552-1557.	1.2	76
287	Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. Circulation, 2016, 134, 1697-1707.	1.6	76
288	Pulmonary artery catheterization in acute coronary syndromes: Insights from the GUSTO IIb and GUSTO III trials. American Journal of Medicine, 2005, 118, 482-488.	0.6	75

#	Article	IF	Citations
289	International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Ejection Fraction. Circulation, 2015, 131, 43-53.	1.6	75
290	Patients With Prolonged Ischemic Chest Pain and Presumed-New Left Bundle Branch Block Have Heterogeneous Outcomes Depending on the Presence of ST-Segment Changes. Journal of the American College of Cardiology, 2005, 46, 29-38.	1.2	74
291	Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. American Heart Journal, 2006, 152, 86-92.	1.2	74
292	Prognostic Significance of ST Segment Shift Early After Resolution of ST Elevation in Patients With Myocardial Infarction Treated With Thrombolytic Therapy: The GUSTO-I ST Segment Monitoring Substudy 11This study was supported by Genentech Canada Inc., Toronto, Ontario, Canada; Kabi Vitrum, Sweden; Bayer, New York, New York; Sanofi Pharmaceuticals, Paris, France; ICI Pharmaceuticals, Wilmington, Delaware; Marquette Electronics, Milwaukee, Wisconsin; Ortivus Medical, Stockholm, Sweden; and Mortara Instrument. Journal of the American College of Cardiology, 1998, 31, 783-789.	1.2	73
293	Risk Factors for In-hospital Nonhemorrhagic Stroke in Patients With Acute Myocardial Infarction Treated With Thrombolysis. Circulation, 1998, 97, 757-764.	1.6	73
294	Primary Percutaneous Coronary Intervention Compared With Fibrinolysis for Myocardial Infarction in Diabetes Mellitus. Archives of Internal Medicine, 2007, 167, 1353.	4.3	73
295	Catheter Ablation for Ventricular Tachycardia in Patients with an Implantable Cardioverter Defibrillator (CALYPSO) Pilot Trial. Journal of Cardiovascular Electrophysiology, 2015, 26, 151-157.	0.8	73
296	Association of Public Health Initiatives With Outcomes for Out-of-Hospital Cardiac Arrest at Home and in Public Locations. JAMA Cardiology, 2017, 2, 1226.	3.0	73
297	Nonâ€“Q-Wave Versus Q-Wave Myocardial Infarction After Thrombolytic Therapy. Circulation, 1998, 97, 444-450.	1.6	72
298	Stroke in Patients With Acute Coronary Syndromes. Circulation, 1999, 99, 2371-2377.	1.6	72
299	Systems Genetics Analysis of Genome-Wide Association Study Reveals Novel Associations Between Key Biological Processes and Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1712-1722.	1.1	72
300	Fibrinolysis Use Among Patients Requiring Interhospital Transfer for ST-Segment Elevation Myocardial Infarction Care. JAMA Internal Medicine, 2015, 175, 207.	2.6	72
301	Prognostic value of isolated troponin elevation across the spectrum of chest pain syndromes. American Journal of Cardiology, 2003, 91, 936-940.	0.7	71
302	Rates of Cardiac Catheterization Cancelation for ST-Segment Elevation Myocardial Infarction After Activation by Emergency Medical Services or Emergency Physicians. Circulation, 2012, 125, 308-313.	1.6	71
303	Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. JAMA Cardiology, 2020, 5, 582.	3.0	71
304	Long-Term Mortality of Patients With Acute Myocardial Infarction in the United States and Canada. Circulation, 2004, 110, 1754-1760.	1.6	70
305	Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISEâ€MI): design and baseline characteristics. European Journal of Heart Failure, 2021, 23, 1040-1048.	2.9	70
306	Prior Coronary Artery Bypass Graft Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2010, 3, 343-351.	1.1	69

#	Article	IF	Citations
307	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. European Heart Journal, 2016, 38, ehv643.	1.0	69
308	An open-Label, 2 Ã— 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. American Heart Journal, 2018, 200, 17-23.	1.2	69
309	Potential impact of evidence-based medicine in acute coronary syndromes: insights from GUSTO-IIb. Journal of the American College of Cardiology, 1998, 32, 2023-2030.	1.2	68
310	Genetics of coronary heart disease: Current knowledge and research principles. American Heart Journal, 2000, 140, S11-S26.	1.2	68
311	Extent of ST-segment depression and cardiac events in non-ST-segment elevation acute coronary syndromes. European Heart Journal, 2005, 26, 2106-2113.	1.0	68
312	Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Journal of the American Heart Association, 2015, 4, .	1.6	68
313	Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2021, 326, 314.	3.8	68
314	Thrombin Generation, Inhibition and Clinical Outcomes in Patients With Acute Myocardial Infarction Treated With Thrombolytic Therapy and Heparin: Results From the GUSTO-I Trial fn1fn1This study was supported by Genentech, Inc., South San Francisco, California; Bayer Corporation, New York, New York; CIBA-Corning, Medfield, Massachusetts; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France.. Journal of the American College of Cardiology, 1998, 31, 497-505.	1.2	67
315	Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. American Heart Journal, 2004, 147, 246-252.	1.2	67
316	Baseline Q-Wave Surpasses Time From Symptom Onset as a Prognostic Marker in ST-Segment Elevation Myocardial Infarction Patients Treated With Primary Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2009, 53, 1503-1509.	1.2	67
317	Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Treated With Glycoprotein IIb/IIIa Inhibitors or Thienopyridines. Journal of the American College of Cardiology, 2009, 54, 468-476.	1.2	67
318	Physical activity in patients with stable coronary heart disease: an international perspective. European Heart Journal, 2013, 34, 3286-3293.	1.0	67
319	Association of neighborhood characteristics with incidence of out-of-hospital cardiac arrest and rates of bystander-initiated CPR: Implications for community-based education intervention. Resuscitation, 2014, 85, 1512-1517.	1.3	67
320	Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. Heart, 2016, 102, 508-517.	1.2	67
321	Improving Care of STEMI in the United States 2008 to 2012. Journal of the American Heart Association, 2019, 8, e008096.	1.6	67
322	Systematic adjudication of myocardial infarction end-points in an international clinical trial. Current Controlled Trials in Cardiovascular Medicine, 2001, 2, 180.	1.5	66
323	Impact of Candesartan on Nonfatal Myocardial Infarction and Cardiovascular Death in Patients With Heart Failure. JAMA - Journal of the American Medical Association, 2005, 294, 1794.	3.8	66
324	The cost of acute myocardial infarction in the new millennium: Evidence from a multinational registry. American Heart Journal, 2006, 151, 206-212.	1.2	66

#	Article	IF	Citations
325	Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes. European Heart Journal, 2004, 25, 313-321.	1.0	65
326	Reperfusion strategies for acute myocardial infarction in the elderly. Journal of the American College of Cardiology, 2005, 45, 471-478.	1.2	65
327	The organization, function, and outcomes of ST-elevation myocardial infarction networks worldwide: current state, unmet needs and future directions. European Heart Journal, 2014, 35, 1526-1532.	1.0	65
328	Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction. JAMA Cardiology, 2018, 3, 391.	3.0	65
329	Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality. European Journal of Heart Failure, 2018, 20, 295-303.	2.9	65
330	International differences in evolution of early discharge after acute myocardial infarction. Lancet, The, 2004, 363, 511-517.	6.3	64
331	Pexelizumab and the APEX AMI Trial. JAMA - Journal of the American Medical Association, 2007, 297, 1877.	3.8	64
332	A Model for Predicting Mortality in Acute ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2010, 3, 414-422.	1.4	64
333	A Guide for a Cardiovascular Genomics Biorepository: the CATHGEN Experience. Journal of Cardiovascular Translational Research, 2015, 8, 449-457.	1.1	64
334	Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis. Journal of the American College of Cardiology, 2019, 73, 2819-2828.	1.2	64
335	Correlation of angiographic findings and right (V1 to V3) versus left (V4 to V6) precordial ST-segment depression in inferior wall acute myocardial infarction. American Journal of Cardiology, 1999, 83, 143-148.	0.7	63
336	Impact of a Statewide ST-Segmentâ€“Elevation Myocardial Infarction Regionalization Program on Treatment Times for Women, Minorities, and the Elderly. Circulation: Cardiovascular Quality and Outcomes, 2010, 3, 514-521.	0.9	63
337	Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial. European Heart Journal, 2010, 31, 1708-1716.	1.0	63
338	Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The Global Registry of Acute Coronary Events. European Heart Journal, 2010, 31, 667-675.	1.0	63
339	Discovery of proteins related to coronary artery disease using industrial-scale proteomics analysis of pooled plasma. American Heart Journal, 2006, 152, 478-485.	1.2	62
340	Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. European Heart Journal, 2015, 36, 669-675.	1.0	62
341	Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus. Circulation, 2020, 141, 843-862.	1.6	62
342	Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: Results from the GUSTO-III trial. American Heart Journal, 2003, 145, 515-521.	1.2	61

#	Article	IF	Citations
343	Association between bleeding, blood transfusion, and costs among patients with nonâ€“ST-segment elevation acute coronary syndromes. American Heart Journal, 2008, 155, 369-374.	1.2	61
344	Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Diabetes Care, 2009, 32, 915-920.	4.3	61
345	Improving diabetes medication adherence: successful, scalable interventions. Patient Preference and Adherence, 2015, 9, 139.	0.8	61
346	Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. American Heart Journal, 2015, 169, 25-30.	1.2	61
347	Pattern of liver enzyme elevations in acute ST-elevation myocardial infarction. Coronary Artery Disease, 2012, 23, 22-30.	0.3	60
348	International differences in in-hospital revascularization and outcomes following acute myocardial infarction A multilevel analysis of patients in ASSENT-2. European Heart Journal, 2003, 24, 1640-1650.	1.0	59
349	Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure, 2010, 12, 557-565.	2.9	59
350	Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 86-94.	1.4	59
351	Clinical Practice Patterns in Temporary Mechanical Circulatory Support for Shock in the Critical Care Cardiology Trials Network (CCCTN) Registry. Circulation: Heart Failure, 2019, 12, e006635.	1.6	58
352	Prophylactic lidocaine use in acute myocardial infarction: Incidence and outcomes from two international trials. American Heart Journal, 1999, 137, 799-805.	1.2	57
353	Differences in the Clinical Features and Outcomes in African Americans and Whites with Myocardial Infarction. American Journal of Medicine, 2006, 119, 70.e1-70.e8.	0.6	57
354	Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention. Circulation, 2019, 140, 1921-1932.	1.6	57
355	Summary of Evidence Regarding Hospital Strategies to Reduce Door-to-Balloon Times for Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Critical Pathways in Cardiology, 2007, 6, 91-97.	0.2	56
356	Spontaneous reperfusion in ST-elevation myocardial infarction: Comparison of angiographic and electrocardiographic assessments. American Heart Journal, 2008, 156, 248-255.	1.2	56
357	Care Processes Associated With Quicker Door-Inâ€“Door-Out Times for Patients With ST-Elevationâ€“Myocardial Infarction Requiring Transfer. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 382-388.	0.9	56
358	Infarct size, left ventricular function, and prognosis in women compared to men after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: results from an individual patient-level pooled analysis of 10 randomized trials. European Heart Journal, 2017, 38, 1656-1663.	1.0	56
359	Strategies of patient care in acute coronary syndromes: rationale for the global registry of acute coronary events (GRACE) registry. American Journal of Cardiology, 2000, 86, 4-9.	0.7	55
360	Prediction of the extent and severity of left ventricular dysfunction in anterior acute myocardial infarction by the admission electrocardiogram. American Heart Journal, 2001, 141, 915-924.	1.2	55

#	Article	IF	Citations
361	Design of the Genetics of Early Onset Cardiovascular Disease (GENECARD) study. American Heart Journal, 2003, 145, 602-613.	1.2	55
362	Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Journal of the American College of Cardiology, 2004, 43, 2153-2159.	1.2	55
363	Acute Kidney Injury and Cardiovascular Outcomes in Acute Severe Hypertension. Circulation, 2010, 121, 2183-2191.	1.6	55
364	Apixaban in patients with atrial fibrillation and prior coronary artery disease: Insights from the ARISTOTLE trial. International Journal of Cardiology, 2013, 170, 215-220.	0.8	55
365	Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes. Cardiovascular Drugs and Therapy, 2017, 31, 545-549.	1.3	55
366	Age and Outcomes in ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. Archives of Internal Medicine, 2011, 171, 559-67.	4.3	54
367	Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction study. American Heart Journal, 2013, 166, 913-919.	1.2	54
368	Novel therapeutics in myocardial infarction: targeting microvascular dysfunction and reperfusion injury. Trends in Pharmacological Sciences, 2015, 36, 605-616.	4.0	54
369	Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the <scp>CHARM</scp>â€study programme. European Journal of Heart Failure, 2016, 18, 1508-1517.	2.9	54
370	Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. American Heart Journal, 2017, 185, 140-149.	1.2	54
371	Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart, 2017, 103, 623-628.	1.2	54
372	Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. American Heart Journal, 2019, 208, 123-131.	1.2	54
373	Canadian-American Differences in the Management of Acute Coronary Syndromes in the GUSTO IIb Trial. Circulation, 2000, 102, 1375-1381.	1.6	53
374	Reperfusion of acute myocardial infarction in North Carolina emergency departments (RACE): Study design. American Heart Journal, 2006, 152, 851.e1-851.e11.	1.2	53
375	Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. European Heart Journal, 2010, 31, 1181-1187.	1.0	53
376	Clinical practices, complications, and mortality in neurological patients with acute severe hypertension: The Studying the Treatment of Acute hyperTension registry. Critical Care Medicine, 2011, 39, 2330-2336.	0.4	53
377	Risk Stratification in the Setting of Non-ST Elevation Acute Coronary Syndromes 1999-2007. American Journal of Cardiology, 2011, 108, 617-624.	0.7	53
378	Organization and staffing practices in US cardiac intensive care units: a survey on behalf of the American Heart Association Writing Group on the Evolution of Critical Care Cardiology. European Heart Journal: Acute Cardiovascular Care, 2013, 2, 3-8.	0.4	53

#	Article	IF	Citations
379	Cardiac tamponade in the fibrinolytic era: Analysis of >100000 patients with ST-segment elevation myocardial infarction. American Heart Journal, 2006, 151, 316-322.	1.2	52
380	Transfusion and mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. European Heart Journal, 2009, 30, 2575-2583.	1.0	52
381	Contribution of cardiac and extraâ€cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. European Journal of Heart Failure, 2018, 20, 504-510.	2.9	52
382	Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. European Journal of Heart Failure, 2019, 21, 974-984.	2.9	52
383	High-Intensity Statin Use Among Patients With Atherosclerosis in the U.S.. Journal of the American College of Cardiology, 2022, 79, 1802-1813.	1.2	52
384	Sensible guidelines for the conduct of large randomized trials. Clinical Trials, 2008, 5, 38-39.	0.7	51
385	Genetic effects in the leukotriene biosynthesis pathway and association with atherosclerosis. Human Genetics, 2009, 125, 217-229.	1.8	51
386	Differences in Level of Care at the End of Life According to Race. American Journal of Critical Care, 2010, 19, 335-343.	0.8	51
387	Delay to reperfusion in patients with acute myocardial infarction presenting to acute care hospitals: an international perspective. European Heart Journal, 2010, 31, 1328-1336.	1.0	51
388	Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.6	51
389	Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. American Heart Journal, 2005, 149, 402-407.	1.2	50
390	Direct Transport to a Percutaneous Cardiac Intervention Center and Outcomes in Patients With Out-of-Hospital Cardiac Arrest. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	50
391	Multistate 5â€Year Initiative to Improve Care for Outâ€ofâ€Hospital Cardiac Arrest: Primary Results From the HeartRescue Project. Journal of the American Heart Association, 2017, 6, .	1.6	50
392	Randomized Trials Versus CommonÂSense and Clinical Observation. Journal of the American College of Cardiology, 2020, 76, 580-589.	1.2	50
393	Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group. European Heart Journal, 2020, 41, 1132-1140.	1.0	50
394	Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarctionâ€"the ASSENT Plus study. European Heart Journal, 2003, 24, 897-908.	1.0	49
395	International Variation in the Use of Blood Transfusion in Patients With Nonâ€"ST-Segment Elevation Acute Coronary Syndromes. American Journal of Cardiology, 2008, 101, 25-29.e2.	0.7	49
396	Initial Aspirin Dose and Outcome Among ST-Elevation Myocardial Infarction Patients Treated With Fibrinolytic Therapy. Circulation, 2008, 117, 192-199.	1.6	49

#	Article	IF	Citations
397	Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI Angiographic Study. European Heart Journal, 2008, 29, 1127-1135.	1.0	49
398	Thrombocytopenia in Patients With an Acute Coronary Syndrome (from the Global Registry of Acute) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.7	49
399	Diagnosing Acute Myocardial Infarction in Patients With Left Bundle Branch Block. American Journal of Cardiology, 2011, 108, 782-788.	0.7	49
400	In-Hospital Switching Between Clopidogrel and Prasugrel Among Patients With Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2014, 7, 585-593.	1.4	49
401	Prediction of 30-Day Mortality Among Patients With Thrombolysis-Related Intracranial Hemorrhage. Circulation, 1998, 98, 1376-1382.	1.6	48
402	Clinical and research issues regarding chronic advanced coronary artery disease Part II: Trial design, outcomes, and regulatory issues. American Heart Journal, 2008, 155, 435-444.	1.2	48
403	Heart Failure Complicating Nonâ€“ST-Segment Elevation Acute Coronary Syndrome. JACC: Heart Failure, 2013, 1, 223-229.	1.9	48
404	Comparison of team-focused CPR vs standard CPR in resuscitation from out-of-hospital cardiac arrest: Results from a statewide quality improvement initiative. Resuscitation, 2016, 105, 165-172.	1.3	48
405	Thrombolysis and Q Wave Versus Non-Q Wave First Acute Myocardial Infarction: A GUSTO-I Substudy. Journal of the American College of Cardiology, 1997, 29, 770-777.	1.2	47
406	Time Course of Degradation of Cardiac Troponin I in Patients With Acute ST-Elevation Myocardial Infarction. Circulation Research, 2006, 99, 1141-1147.	2.0	47
407	Prevalence and prognostic impact of bundle branch block in patients with heart failure: Evidence from the CHARM programme. European Journal of Heart Failure, 2007, 9, 510-517.	2.9	47
408	Mortality and Morbidity Reduction by Primary Percutaneous Coronary Intervention Is Independent of the Patient's Age. JACC: Cardiovascular Interventions, 2010, 3, 324-331.	1.1	47
409	The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events. American Journal of Medicine, 2002, 112, 647-658.	0.6	46
410	Unraveling the spectrum of left bundle branch block in acute myocardial infarction: Insights from the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT 2 and 3) trials. American Heart Journal, 2006, 151, 10-15.	1.2	45
411	The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarction. European Heart Journal, 2007, 28, 415-424.	1.0	45
412	Bringing cardiovascular cell-based therapy to clinical application: Perspectives based on a National Heart, Lung, and Blood Institute Cell Therapy Working Group meeting. American Heart Journal, 2007, 153, 732-742.	1.2	45
413	Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry. American Heart Journal, 2009, 157, 651-657.	1.2	45
414	Metabolic profiles predict adverse events after coronary artery bypass grafting. Journal of Thoracic and Cardiovascular Surgery, 2012, 143, 873-878.	0.4	45

#	Article	IF	Citations
415	Rescuing clinical trials in the United States and beyond: A call for action. American Heart Journal, 2013, 165, 837-847.	1.2	45
416	Relation of Increased Arterial Blood Pressure to Mortality and Stroke in the Context of Contemporary Thrombolytic Therapy for Acute Myocardial Infarction. Annals of Internal Medicine, 1996, 125, 891.	2.0	44
417	Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: Experience from the GUSTO-I Trial. American Heart Journal, 1999, 138, 493-499.	1.2	44
418	Regional systems of care demonstration project: Mission: Lifeline STEMI Systems Accelerator: Design and methodology. American Heart Journal, 2014, 167, 15-21.e3.	1.2	44
419	Lipoproteinâ€Associated Phospholipase A ₂ Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. Journal of the American Heart Association, 2016, 5, .	1.6	44
420	Association of Rapid Care Process Implementation on Reperfusion Times Across Multiple ST-Segmentâ€“Elevation Myocardial Infarction Networks. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	44
421	The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes. Journal of the American College of Cardiology, 2002, 39, 22-29.	1.2	43
422	Dynamic prognostication in non-STâ€“elevation acute coronary syndromes: insights from GUSTO-IIB and pursuit. American Heart Journal, 2004, 148, 62-71.	1.2	43
423	Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes. European Heart Journal, 2006, 27, 527-533.	1.0	43
424	Clinical and research issues regarding chronic advanced coronary artery disease. American Heart Journal, 2008, 155, 418-434.	1.2	43
425	Influence of Hospitalization for Cardiovascular Versus Noncardiovascular Reasons on Subsequent Mortality in Patients With Chronic Heart Failure Across the Spectrum of Ejection Fraction. Circulation: Heart Failure, 2014, 7, 895-902.	1.6	43
426	Clinical Outcomes According to Baseline Blood Pressure in Patients With a Low Ejection Fraction in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) Program. Journal of the American College of Cardiology, 2008, 52, 2000-2007.	1.2	42
427	Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: Results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. American Heart Journal, 2013, 166, 549-558.	1.2	42
428	Delays in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction Patients Presenting With Cardiogenic Shock. JACC: Cardiovascular Interventions, 2018, 11, 1824-1833.	1.1	42
429	Oral Anticoagulation and Cardiovascular Outcomes in Patients With Atrial Fibrillation and End-Stage Renal Disease. Journal of the American College of Cardiology, 2020, 75, 1299-1308.	1.2	42
430	Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)â€“5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with nonâ€“ST-segment elevation acute coronary syndromes. American Heart Journal, 2005, 150, 1107.e1-1107.e10.	1.2	41
431	Effect of Smoking on Outcomes of Primary PCI in Patients With STEMI. Journal of the American College of Cardiology, 2020, 75, 1743-1754.	1.2	41
432	Influence of insurance type on the use of procedures, medications and hospital outcome in patients with unstable angina: results from the GUARANTEE registry. Journal of the American College of Cardiology, 1998, 32, 387-392.	1.2	40

#	Article	IF	Citations
433	Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. European Heart Journal, 2008, 29, 3022-3028.	1.0	40
434	Hospital Length of Stay in Patients with Non-ST-segment Elevation Myocardial Infarction. American Journal of Medicine, 2012, 125, 1085-1094.	0.6	40
435	Multistate implementation of guideline-based cardiac resuscitation systems of care: Description of the HeartRescue Project. American Heart Journal, 2013, 166, 647-653.e2.	1.2	40
436	Development and validation of a prioritization rule for obtaining an immediate 12-lead electrocardiogram in the emergency department to identify ST-elevation myocardial infarction. American Heart Journal, 2012, 163, 372-382.	1.2	39
437	Serious Infection After Acute Myocardial Infarction. JACC: Cardiovascular Interventions, 2012, 5, 769-776.	1.1	39
438	Long-Term Post-Discharge Risks in Older Survivors of Myocardial Infarction With and Without Out-of-Hospital Cardiac Arrest. Journal of the American College of Cardiology, 2016, 67, 1981-1990.	1.2	39
439	Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the assessment of the safety of a new thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction. American Heart Journal, 2004, 147, 993-998.	1.2	38
440	Warfarin Use and Outcomes in Patients with Atrial Fibrillation Complicating Acute Coronary Syndromes. American Journal of Medicine, 2010, 123, 134-140.	0.6	38
441	Chronic obstructive pulmonary disease in patients with atrial fibrillation: Insights from the ARISTOTLE trial. International Journal of Cardiology, 2016, 202, 589-594.	0.8	38
442	Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: A systematic overview. American Heart Journal, 2006, 152, 291-296.	1.2	37
443	Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. European Heart Journal, 2008, 29, 315-323.	1.0	37
444	Pexelizumab and Infarct Size in Patients With Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Imaging, 2010, 3, 52-60.	2.3	37
445	Hypertensive heart failure: patient characteristics, treatment, and outcomes. American Journal of Emergency Medicine, 2011, 29, 855-862.	0.7	37
446	Atrial Fibrillation and Acute Myocardial Infarction: Antithrombotic Therapy and Outcomes. American Journal of Medicine, 2012, 125, 897-905.	0.6	37
447	Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation: An ARISTOTLE Substudy. Clinical Chemistry, 2015, 61, 368-378.	1.5	37
448	Heart Rhythm Monitoring Strategies for Cryptogenic Stroke: 2015ÂDiagnostics and Monitoring Stroke Focus Group Report. Journal of the American Heart Association, 2016, 5, e002944.	1.6	37
449	Risk stratification for stroke in atrial fibrillation: a critique. European Heart Journal, 2019, 40, 1294-1302.	1.0	37
450	Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. Journal of the American Heart Association, 2020, 9, e018984.	1.6	37

#	Article	IF	Citations
451	Assessing the Role of Rare Genetic Variation in Patients With Heart Failure. JAMA Cardiology, 2021, 6, 379.	3.0	37
452	Racial differences in the management of unstable angina: Results from the multicenter GUARANTEE registry. American Heart Journal, 1999, 138, 1065-1072.	1.2	36
453	Predictors of death and reinfarction at 30 days after primary angioplasty: The GUSTO IIb and RAPPORT trials. American Heart Journal, 2000, 139, 476-481.	1.2	36
454	Attenuation of Rebound Ischemia After Discontinuation of Heparin Therapy by Glycoprotein IIb/IIIa Inhibition With Eptifibatide in Patients With Acute Coronary Syndromes. Circulation, 2001, 104, 2772-2777.	1.6	36
455	Grade III Ischemia on Presentation with Acute Myocardial Infarction Predicts Rapid Progression of Necrosis and Less Myocardial Salvage with Thrombolysis. Cardiology, 2002, 97, 166-174.	0.6	36
456	Association of Mortality With Years of Education in Patients With ST-Segment Elevation Myocardial Infarction Treated With Fibrinolysis. Journal of the American College of Cardiology, 2011, 57, 138-146.	1.2	36
457	High-risk patients with ST-elevation myocardial infarction derive greatest absolute benefit from primary percutaneous coronary intervention: Results from the Primary Coronary Angioplasty Trialist versus Thrombolysis (PCAT)-2 Collaboration. American Heart Journal, 2011, 161, 500-507.e1.	1.2	36
458	Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. American Heart Journal, 2012, 164, 43-51.	1.2	36
459	Stroke After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2013, 6, 176-183.	1.4	36
460	Strategic Transformation of Population Studies: Recommendations of the Working Group on Epidemiology and Population Sciences From the National Heart, Lung, and Blood Advisory Council and Board of External Experts. American Journal of Epidemiology, 2015, 181, 363-368.	1.6	36
461	Organizational Structure, Staffing, Resources, and Educational Initiatives in Cardiac Intensive Care Units in the United States. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, e003864.	0.9	36
462	A comparison of U.S. and Canadian cardiac catheterization practices in detecting severe coronary artery disease after myocardial infarction: efficiency, yield and long-term implications. Journal of the American College of Cardiology, 1999, 34, 12-19.	1.2	35
463	Diabetes and ischemic heart disease. American Heart Journal, 1999, 138, S366-S375.	1.2	35
464	International variation in the use of evidence-based medicines for acute coronary syndromes. European Heart Journal, 2003, 24, 2133-2141.	1.0	35
465	Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal, 2005, 27, 1447-1458.	1.0	35
466	Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: Findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS. American Heart Journal, 2006, 152, 684.e1-684.e9.	1.2	35
467	Development of Systems of Care for ST-Elevation Myocardial Infarction Patients. Circulation, 2007, 116, e55-9.	1.6	35
468	Paramedic transtelephonic communication to cardiologist of clinical and electrocardiographic assessment for rapid reperfusion of ST-elevation myocardial infarction. Journal of Electrocardiology, 2007, 40, 265-270.	0.4	35

#	Article	IF	Citations
469	Cardiogenic shock and heart failure postâ€“percutaneous coronary intervention in ST-elevation myocardial infarction: Observations from â€œAssessment of Pexelizumab in Acute Myocardial Infarctionâ€• American Heart Journal, 2011, 162, 89-97.	1.2	35
470	The Systemic Inflammatory Response Syndrome in Patients With ST-Segment Elevation Myocardial Infarction*. Critical Care Medicine, 2013, 41, 2080-2087.	0.4	35
471	Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. European Heart Journal, 2015, 36, ehv447.	1.0	35
472	Health Information Technology: Meaningful Use and Next Steps to Improving Electronic Facilitation of Medication Adherence. JMIR Medical Informatics, 2016, 4, e9.	1.3	35
473	Frequency, significance, and cost of recurrent ischemia after thrombolytic therapy for acute Myocardial Infarction. American Journal of Cardiology, 1995, 76, 1007-1013.	0.7	34
474	Comparison of outcomes of patients with myocardial infarction when living alone versus those not living alone. American Journal of Cardiology, 2002, 90, 1374-1377.	0.7	34
475	Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: An APEX AMI substudy. International Journal of Cardiology, 2013, 168, 2127-2133.	0.8	34
476	Antiplatelet and anticoagulation agents in acute coronary syndromes: What is the current status and what does the future hold?. American Heart Journal, 2014, 168, 611-621.	1.2	34
477	Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. Journal of the American Heart Association, 2017, 6, .	1.6	34
478	Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation. Circulation, 2018, 138, 1666-1676.	1.6	34
479	Prediction of Residual Risk by Ceramideâ€Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy. Journal of the American Heart Association, 2020, 9, e015258.	1.6	34
480	Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community. Circulation, 2021, 144, 74-84.	1.6	34
481	Guidelines for Cardiovascular Risk Reduction in Patients With Type 2ÂDiabetes. Journal of the American College of Cardiology, 2022, 79, 1849-1857.	1.2	34
482	Smoking status and outcome after primary coronary angioplasty for acute myocardial infarction. American Heart Journal, 1999, 137, 612-620.	1.2	33
483	Identification, Diagnosis and Treatment of Heparin-induced Thrombocytopenia and Thrombosis: A Registry of Prolonged Heparin Use and Thrombocytopenia among Hospitalized Patients with and without Cardiovascular Disease. Journal of Thrombosis and Thrombolysis, 2005, 19, 11-19.	1.0	33
484	Usefulness of the QRS Score as a Strong Prognostic Marker in Patients Discharged After Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2010, 106, 630-634.	0.7	33
485	Reclassification of cardiovascular risk using integrated clinical and molecular biosignatures: Design of and rationale for the Measurement to Understand the Reclassification of Disease of Cabarrus and Kannapolis (MURDOCK) Horizon 1 Cardiovascular Disease Study. American Heart Journal, 2010, 160, 371-379.e2.	1.2	33
486	Transplant Center Variability in Organ Offer Acceptance and Mortality Among US Patients on the Heart Transplant Waitlist. JAMA Cardiology, 2020, 5, 660.	3.0	33

#	Article	IF	Citations
487	Time Delay, Infarct Size, and Microvascular Obstruction After Primary Percutaneous Coronary Intervention for ST-Segmentâ€“Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2021, 14, e009879.	1.4	33
488	Treating menstruating women with thrombolytic therapy: Insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial. Journal of the American College of Cardiology, 1995, 26, 1651-1656.	1.2	32
489	Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial). American Journal of Cardiology, 2005, 95, 614-618.	0.7	32
490	Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data. Cmaj, 2006, 174, 1421-1426.	0.9	32
491	From Coronary Care Units to Cardiac Intensive Care Units: Recommendations for Organizational, Staffing, and Educational Transformation. Canadian Journal of Cardiology, 2016, 32, 1204-1213.	0.8	32
492	Comparison of primary coronary angioplasty versus thrombolysis in patients with ST-segment elevation acute myocardial infarction and grade II and grade III myocardial ischemia on the enrollment electrocardiogram. American Journal of Cardiology, 2001, 88, 842-847.	0.7	31
493	The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb. Journal of Thrombosis and Thrombolysis, 2002, 14, 91-101.	1.0	31
494	Genetic and functional association of FAM5C with myocardial infarction. BMC Medical Genetics, 2008, 9, 33.	2.1	31
495	Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. Heart, 2010, 96, 838-842.	1.2	31
496	Race, Bleeding, and Outcomes in STEMI Patients Treated with Fibrinolytic Therapy. American Journal of Medicine, 2011, 124, 48-57.	0.6	31
497	Enhancing the efficacy of delivering reperfusion therapy: A European and North American experience with ST-segment elevation myocardial infarction networks. American Heart Journal, 2013, 165, 123-132.	1.2	31
498	Do stable nonâ€“ST-segment elevation acute coronary syndromes require admission to coronary care units?. American Heart Journal, 2016, 175, 184-192.	1.2	31
499	Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2018, 72, 721-733.	1.2	31
500	Gaps in Evidenceâ€Based Therapy Use in Insured Patients in the United States With Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease. Journal of the American Heart Association, 2021, 10, e016835.	1.6	31
501	Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial. Circulation, 2021, 144, 1738-1746.	1.6	31
502	TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: A pooled analysis. American Heart Journal, 1997, 133, 273-282.	1.2	30
503	Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensinâ€converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)â€Added trial. European Journal of Heart Failure, 2008, 10, 157-163.	2.9	30
504	Prehospital system delay in ST-segment elevation myocardial infarction care: A novel linkage of emergency medicine services and inhospital registry data. American Heart Journal, 2013, 165, 363-370.	1.2	30

#	Article	IF	Citations
505	Bypassing the Emergency Department and Time to Reperfusion in Patients With Prehospital ST-Segmentâ€“Elevation. Circulation: Cardiovascular Interventions, 2013, 6, 399-406.	1.4	30
506	Prolonged cardiopulmonary resuscitation and outcomes after out-of-hospital cardiac arrest. Resuscitation, 2016, 105, 45-51.	1.3	30
507	Use of Lipid-, Blood Pressureâ€“, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. JAMA Network Open, 2022, 5, e2148030.	2.8	30
508	Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: The Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy. American Heart Journal, 2003, 145, 636-642.	1.2	29
509	Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction. European Heart Journal, 2006, 27, 419-426.	1.0	29
510	Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy. American Heart Journal, 2010, 160, 272-278.	1.2	29
511	Association Between Cardiac Catheterization Laboratory Pre-Activation and Reperfusion Timing Metrics and Outcomes in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 1837-1847.	1.1	29
512	Heparin dosing and outcome in acute coronary syndromes: The GUSTO-IIb experience. American Heart Journal, 2002, 144, 73-80.	1.2	28
513	Prediction and Prevention of Chemotherapy-Induced Cardiomyopathy. Circulation, 2006, 114, 2432-2433.	1.6	28
514	Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: Outcomes and treatment effect across different levels of risk. American Heart Journal, 2009, 157, 502-508.	1.2	28
515	Resolution of ST-segment depression: a new prognostic marker in ST-segment elevation myocardial infarction. European Heart Journal, 2010, 31, 573-581.	1.0	28
516	Clinical trials and registries in cardiovascular disease: competitive or complementary?. European Heart Journal, 2010, 31, 520-521.	1.0	28
517	Known and missing left ventricular ejection fraction and survival in patients with heart failure: a MAGGIC metaâ€analysis report. European Journal of Heart Failure, 2013, 15, 1220-1227.	2.9	28
518	The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation. JAMA Cardiology, 2017, 2, 324.	3.0	28
519	Temporary Emergency Guidance to STEMI Systems of Care During the COVID-19 Pandemic. Circulation, 2020, 142, 199-202.	1.6	28
520	Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial. Journal of the American College of Cardiology, 2020, 75, 1145-1155.	1.2	28
521	Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. Circulation, 2022, 145, 87-89.	1.6	28
522	Adenosine for Myocardial Protection in Acute Myocardial Infarction. American Journal of Cardiology, 1997, 79, 44-48.	0.7	27

#	Article	IF	Citations
523	Clinical and electrocardiographic variables associated with increased risk of ventricular septal defect in acute anterior myocardial infarction. American Journal of Cardiology, 2000, 86, 830-834.	0.7	27
524	Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry. American Journal of Medicine, 2000, 109, 489-492.	0.6	27
525	Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention. American Journal of Cardiology, 2001, 88, 1403-1406.	0.7	27
526	ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction. European Heart Journal, 2003, 24, 1515-1522.	1.0	27
527	Adverse outcomes in fibrinolytic-based facilitated percutaneous coronary intervention: insights from the ASSENT-4 PCI electrocardiographic substudy. European Heart Journal, 2008, 29, 871-879.	1.0	27
528	ACCF/AHA 2011 Health Policy Statement on Therapeutic Interchange and Substitution. Journal of the American College of Cardiology, 2011, 58, 1287-1307.	1.2	27
529	Recalibration of the Global Registry of Acute Coronary Events risk score in a multiethnic Asian population. American Heart Journal, 2011, 162, 291-299.	1.2	27
530	Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term rIsk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISease (TIGRIS) observational study. International Journal of Cardiology, 2017, 236, 54-60.	0.8	27
531	Timing of Loading Dose of Atorvastatin in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes. JAMA Cardiology, 2018, 3, 1113.	3.0	27
532	Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Journal of the American College of Cardiology, 2001, 37, 1001-1007.	1.2	26
533	Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: Results from 4 large clinical trials. American Heart Journal, 2006, 151, 16-24.	1.2	26
534	Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure. European Heart Journal, 2008, 30, 338-345.	1.0	26
535	Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: Lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. American Heart Journal, 2010, 159, 988-997.	1.2	26
536	Mortality Implications of Primary Percutaneous Coronary Intervention Treatment Delays: Insights From the Assessment of Pexelizumab in Acute Myocardial Infarction Trial. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 183-192.	0.9	26
537	Reasons for Noncompletion of Advance Directives in a Cardiac Intensive Care Unit. American Journal of Critical Care, 2012, 21, 311-320.	0.8	26
538	Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for nonâ€vitamin K antagonist oral anticoagulant dose adjustment. European Journal of Heart Failure, 2016, 18, 1162-1171.	2.9	26
539	Implementation of a Regional Network for STâ€Segmentâ€“Elevation Myocardial Infarction (STEMI) Care and 30â€Day Mortality in a Lowâ€to Middleâ€Income City in Brazil: Findings From Salvador's STEMI Registry (RESISST). Journal of the American Heart Association, 2018, 7, .	1.6	26
540	Higher T-Wave Amplitude Associated With Better Prognosis in Patients Receiving Thrombolytic Therapy for Acute Myocardial Infarction (a GUSTO-I Substudy) 11This study was funded by grants from Bayer, New York, New York; CIBA-Corning, Medfield, Massachusetts; Genentech, South San Francisco, California; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France.. American Journal of Cardiology, 1998, 81, 1078-1084.	0.7	25

#	Article	IF	Citations
541	N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction. Canadian Journal of Cardiology, 2006, 22, 393-397.	0.8	25
542	No Association of Coronary Artery Disease with X-Chromosomal Variants in Comprehensive International Meta-Analysis. Scientific Reports, 2016, 6, 35278.	1.6	25
543	Relation between inhibition of platelet aggregation and clinical outcomes. American Heart Journal, 1998, 136, s43-s50.	1.2	24
544	Hypertension and Diabetes and the Fosinopril Versus Amlodipine Cardiovascular Events Trial (FACET): More ammunition against surrogate end points. Diabetes Care, 1998, 21, 655-657.	4.3	24
545	Effects of Stroke on Medical Resource Use and Costs in Acute Myocardial Infarction. Circulation, 1999, 99, 370-376.	1.6	24
546	Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention. European Heart Journal, 2005, 26, 2396-2403.	1.0	24
547	Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: The CHARM Program. European Journal of Heart Failure, 2006, 8, 191-197.	2.9	24
548	Impact of TIMI 3 patency before primary percutaneous coronary intervention for ST-elevation myocardial infarction on clinical outcome: results from the ASSENT-4 PCI study. European Heart Journal: Acute Cardiovascular Care, 2012, 1, 136-142.	0.4	24
549	The Study Of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): Design and rationale. American Heart Journal, 2012, 164, 646-653.e3.	1.2	24
550	Comparison of Incidence of Bleeding and Mortality of Men Versus Women With ST-Elevation Myocardial Infarction Treated With Fibrinolysis. American Journal of Cardiology, 2012, 109, 320-326.	0.7	24
551	Prognostic implications of creatine kinaseâ€“MB measurements in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. American Heart Journal, 2014, 168, 503-511.e2.	1.2	24
552	Long-term mortality of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation for acute and stable coronary artery disease. International Journal of Cardiology, 2015, 184, 108-114.	0.8	24
553	North American Thrombosis Forum, AF Action Initiative Consensus Document. American Journal of Medicine, 2016, 129, S1-S29.	0.6	24
554	Antithrombotics. Journal of the American College of Cardiology, 2019, 74, 699-711.	1.2	24
555	Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial. Circulation, 2020, 141, 10-20.	1.6	24
556	A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: The U.S. Ecadotril Pilot Safety Study. American Heart Journal, 1999, 138, 1140-1148.	1.2	23
557	Serum Lipids in the GENECARD Study of Coronary Artery Disease Identify Quantitative Trait Loci and Phenotypic Subsets on Chromosomes 3q and 5q. Annals of Human Genetics, 2006, 70, 738-748.	0.3	23
558	Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE). American Heart Journal, 2007, 153, 960-969.	1.2	23

#	Article	IF	Citations
559	Time to reperfusion in acute myocardial infarction. It is time to reduce it!. Journal of Electrocardiology, 2007, 40, 257-264.e6.	0.4	23
560	Polymorphisms of the Tumor Suppressor Gene LSAMP are Associated with Left Main Coronary Artery Disease. Annals of Human Genetics, 2008, 72, 443-453.	0.3	23
561	Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients. American Heart Journal, 2012, 164, 607-615.	1.2	23
562	Large streamlined trials in cardiovascular disease. European Heart Journal, 2014, 35, 544-548.	1.0	23
563	Renal failure in patients with ST-segment elevation acute myocardial infarction treated with primary percutaneous coronary intervention: Predictors, clinical and angiographic features, and outcomes. American Heart Journal, 2016, 173, 57-66.	1.2	23
564	FIRST MEDICAL CONTACT TO DEVICE TIME IN STEMI PATIENTS PRESENTING WITH CARDIOGENIC SHOCK: INSIGHTS FROM MISSION, A LIFELINE STEMI SYSTEMS ACCELERATOR. Journal of the American College of Cardiology, 2017, 69, 1188.	1.2	23
565	Management of Atrial Fibrillation in Older Patients by Morbidity Burden: Insights From Get With The Guidelinesâ€Atrial Fibrillation. Journal of the American Heart Association, 2020, 9, e017024.	1.6	23
566	Antithrombotic Treatment of Embolic Stroke of Undetermined Source. Stroke, 2020, 51, 1758-1765.	1.0	23
567	Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale. Stroke, 2021, 52, 1065-1068.	1.0	23
568	Arrhythmias Other Than Atrial Fibrillation in Those With an Irregular Pulse Detected With a Smartwatch: Findings From the Apple Heart Study. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e010063.	2.1	23
569	Outcomes of diabetic patients following acute myocardial infarction. Coronary Artery Disease, 1996, 7, 732-743.	0.3	22
570	Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. Journal of the American College of Cardiology, 2003, 42, 1178-1185.	1.2	22
571	Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial). American Journal of Cardiology, 2004, 93, 458-461.	0.7	22
572	Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2	0.7	22
573	Using Measures of Disease Progression to Determine Therapeutic Effect. Journal of the American College of Cardiology, 2006, 48, 434-437.	1.2	22
574	Impact of Initial Heart Rate and Systolic Blood Pressure on Relation of Age and Mortality Among Fibrinolytic-Treated Patients With Acute ST-Elevation Myocardial Infarction Presenting With Cardiogenic Shock. American Journal of Cardiology, 2007, 99, 793-796.	0.7	22
575	ALOX5AP variants are associated with in-stent restenosis after percutaneous coronary intervention. Atherosclerosis, 2008, 201, 148-154.	0.4	22
576	Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. Journal of Thrombosis and Thrombolysis, 2012, 34, 106-113.	1.0	22

#	Article	IF	Citations
577	Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy. Trials, 2013, 14, 123.	0.7	22
578	Diurnal variations in incidence and outcome of out-of-hospital cardiac arrest including prior comorbidity and pharmacotherapy: A nationwide study in Denmark. Resuscitation, 2014, 85, 1161-1168.	1.3	22
579	Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by) Tj ETQq1 1 0.784314 rgBT /Ov	0.7	22
580	Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF. American Heart Journal, 2020, 220, 41-50.	1.2	22
581	Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: Results of GUSTO-I. American Heart Journal, 1998, 136, 868-876.	1.2	21
582	Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies. American Heart Journal, 2003, 146, 958-968.	1.2	21
583	Relationship of Incorrect Dosing of Fibrinolytic Therapy and Clinical Outcomes. JAMA - Journal of the American Medical Association, 2005, 293, 1746.	3.8	21
584	Predictors of 90-day readmission among patients with acute severe hypertension. The cross-sectional observational Studying the Treatment of Acute hyperTension (STAT) study. American Heart Journal, 2010, 160, 521-527.e1.	1.2	21
585	Transport Time and Care Processes for Patients Transferred With ST-Segmentâ€“Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2012, 5, 555-562.	1.4	21
586	Assessment of Temporal Trends in Mortality With Implementation of a Statewide ST-Segment Elevation Myocardial Infarction (STEMI) Regionalization Program. Annals of Emergency Medicine, 2012, 59, 243-252.e1.	0.3	21
587	Fine mapping of a linkage peak with integration of lipid traits identifies novel coronary artery disease genes on chromosome 5. BMC Genetics, 2012, 13, 12.	2.7	21
588	The effect of indapamide versus hydrochlorothiazide on ventricular and arterial function in patients with hypertension and diabetes: Results of a randomized trial. American Heart Journal, 2014, 168, 446-456.	1.2	21
589	Safety of the weight-adjusted dosing regimen of tenecteplase in the ASSENT-Trial. American Journal of Cardiology, 2001, 88, 1240-1245.	0.7	20
590	Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin. Stroke, 2017, 48, 3266-3273.	1.0	20
591	Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time. Journal of the American Heart Association, 2017, 6, .	1.6	20
592	Comparative Effectiveness of Î²-Blocker Use Beyond 3 Years After Myocardial Infarction and Long-Term Outcomes Among Elderly Patients. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005103.	0.9	20
593	Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. JACC: Heart Failure, 2019, 7, 418-427.	1.9	20
594	Electrocardiographic infarct size assessment after thrombolysis: Insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial. American Heart Journal, 2005, 150, 659-665.	1.2	19

#	Article	IF	Citations
595	Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: A substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trial. American Heart Journal, 2010, 159, 131-140.	1.2	19
596	Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): A randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with nonâ€“ST-segment elevation acute coronary syndromes initially treated with fondaparinux. American Heart Journal, 2010, 160, 1029-1034.e1.	1.2	19
597	ACCF/AHA 2011 Health Policy Statement on Therapeutic Interchange and Substitution. Circulation, 2011, 124, 1290-1310.	1.6	19
598	Transfer Times and Outcomes in Patients With ST-Segmentâ€“Elevation Myocardial Infarction Undergoing Interhospital Transfer for Primary Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 437-444.	0.9	19
599	The forgotten lead: Does aVR ST-deviation add insight into the outcomes of ST-elevation myocardial infarction patients?. American Heart Journal, 2013, 166, 333-339.	1.2	19
600	Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation. Heart, 2019, 105, 235-242.	1.2	19
601	Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. American Heart Journal, 2020, 221, 1-8.	1.2	19
602	Changes in Care Delivery for Patients With Heart Failure During the COVID-19 Pandemic: Results of a Multicenter Survey. Journal of Cardiac Failure, 2020, 26, 635-636.	0.7	19
603	Patient outcomes after fibrinolytic therapy for acute myocardial infarction at hospitals with and without coronary revascularization capability. Journal of the American College of Cardiology, 2002, 40, 1034-1040.	1.2	18
604	Prognostic value of predischarge electrocardiographic measurement of infarct size after thrombolysis: Insights from GUSTO I Economics and Quality of Life substudy. American Heart Journal, 2004, 148, 795-802.	1.2	18
605	Antithrombotic drug development for atrial fibrillation: Proceedings, Washington, DC, July 25-27, 2005. American Heart Journal, 2008, 155, 829-840.	1.2	18
606	Does silent myocardial infarction add prognostic value in ST-elevation myocardial infarction patients without a history of prior myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial. American Heart Journal, 2010, 160, 671-677.	1.2	18
607	Direct Transfer From the Referring Hospitals to the Catheterization Laboratory to Minimize Reperfusion Delays for Primary Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2015, 8, e002477.	1.4	18
608	The Unmet Need for Addressing Cardiac Issues in Intensive Care Research*. Critical Care Medicine, 2015, 43, 128-134.	0.4	18
609	Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective. JAMA Cardiology, 2017, 2, 525.	3.0	18
610	Impact of Regional Systems of Care on Disparities in Care Among Female and Black Patients Presenting With STâ€Segmentâ€“Elevation Myocardial Infarction. Journal of the American Heart Association, 2017, 6, .	1.6	18
611	Association of Bystander and Firstâ€Responder Efforts and Outcomes According to Sex: Results From the North Carolina HeartRescue Statewide Quality Improvement Initiative. Journal of the American Heart Association, 2018, 7, e009873.	1.6	18
612	Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62 T	0.7	18

#	Article	IF	Citations
613	Predicting risk of cardiovascular events 1 to 3â€‰years postâ€myocardial infarction using a global registry. Clinical Cardiology, 2020, 43, 24-32.	0.7	18
614	Safety and efficacy outcomes of left atrial posterior wall isolation compared to pulmonary vein isolation and pulmonary vein isolation with linear ablation for the treatment of persistent atrial fibrillation. American Heart Journal, 2020, 220, 89-96.	1.2	18
615	Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease. Heart, 2021, 107, 1739-1747.	1.2	18
616	Health-related quality of life 1â€“3 years post-myocardial infarction: its impact on prognosis. Open Heart, 2021, 8, e001499.	0.9	18
617	Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. Cardiovascular Research, 2022, 118, 2112-2123.	1.8	18
618	Treating Patients With Acute Coronary Syndromes With Aggressive Antiplatelet Therapy (from the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.7	17
619	Differences Between Local Hospital and Core Laboratory Interpretation of the Admission Electrocardiogram in Patients With Acute Coronary Syndromes and Their Relation to Outcome. American Journal of Cardiology, 2007, 100, 169-174.	0.7	17
620	The Impact of Place of Enrollment and Delay to Reperfusion on 90-Day Post-Infarction Mortality in the ASSENT-4 PCI Trial. JACC: Cardiovascular Interventions, 2009, 2, 925-930.	1.1	17
621	Do baseline atrial electrocardiographic and infarction patterns predict new-onset atrial fibrillation after ST-elevation myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial. Journal of Electrocardiology, 2010, 43, 351-358.	0.4	17
622	Relative Prognostic Value of Baseline Q Wave and Time from Symptom Onset Among Men and Women With ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2012, 110, 1555-1560.	0.7	17
623	Simultaneous Consideration of Multiple Candidate Protein Biomarkers for Long-Term Risk for Cardiovascular Events. Circulation: Cardiovascular Genetics, 2015, 8, 168-177.	5.1	17
624	Enhancing the value of clinical trials: the role of data sharing. Nature Reviews Cardiology, 2016, 13, 629-630.	6.1	17
625	Relationship between therapeutic effects on infarct size in acute myocardial infarction and therapeutic effects on 1-year outcomes: A patient-level analysis of randomized clinical trials. American Heart Journal, 2017, 188, 18-25.	1.2	17
626	Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial. American Heart Journal, 2018, 197, 133-141.	1.2	17
627	Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation. Journal of Thrombosis and Haemostasis, 2021, 19, 2726-2737.	1.9	17
628	Thresholds for the electrocardiographic change range of biochemical markers of acute myocardial infarction (GUSTO-IIa data). American Journal of Cardiology, 2002, 90, 233-237.	0.7	16
629	Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial. European Heart Journal, 2005, 26, 1506-1512.	1.0	16
630	Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction. American Heart Journal, 2006, 151, 787-790.	1.2	16

#	Article	IF	Citations
631	A Pint of Sweat Will Save a Gallon of Blood. Circulation, 2014, 129, 1190-1192.	1.6	16
632	How can we optimize the processes of care for acute coronary syndromes to improve outcomes?. American Heart Journal, 2014, 168, 622-631.e2.	1.2	16
633	Clinical characteristics and outcomes of patients with angina and heart failure in the <scp>CHARM</scp> (Candesartan in Heart Failure Assessment of Reduction in Mortality and) Tj ETQq1 1 0.784314 rgBT /Overlock 10	2.9	16
634	History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. American Heart Journal, 2016, 175, 175-183.	1.2	16
635	Exploring patientâ€“provider decision-making for use of anticoagulation for stroke prevention in atrial fibrillation: Results of the INFORM-AF study. European Journal of Cardiovascular Nursing, 2019, 18, 280-288.	0.4	16
636	FDA-Catalystâ€”Using FDAâ€™s Sentinel Initiative for large-scale pragmatic randomized trials: Approach and lessons learned during the planning phase of the first trial. Clinical Trials, 2019, 16, 90-97.	0.7	16
637	Fibrin modification by ionic and nonionic contrast media during cardiac catheterization. American Journal of Cardiology, 1992, 69, 821-823.	0.7	15
638	Significance of Hemoptysis Following Thrombolytic Therapy For Acute Myocardial Infarction. Chest, 1996, 109, 727-729.	0.4	15
639	Outcome of hispanic patients treated with thrombolytic therapy for acute myocardial infarction. Journal of the American College of Cardiology, 1999, 34, 1729-1737.	1.2	15
640	Persistence of the prothrombotic state after acute coronary syndromes: Implications for treatment. American Heart Journal, 2002, 143, 205-216.	1.2	15
641	Use of proven therapies in nonâ€“ST-elevation acute coronary syndromes according to evidence-based risk stratification. American Heart Journal, 2007, 153, 493-499.	1.2	15
642	Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure â€“ Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure, 2010, 12, 738-745.	2.9	15
643	Spinal Anesthesia for Orthopedic Surgery. Regional Anesthesia and Pain Medicine, 2011, 36, 51-55.	1.1	15
644	Underuse of oral anticoagulants in privately insured patients with atrial fibrillation: A population being targeted by the IMplementation of a randomized controlled trial to imProve treatment with oral AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AFib). American Heart Journal, 2020, 229, 110-117.	1.2	15
645	Extracellular vesicles in atrial fibrillation and stroke. Thrombosis Research, 2020, 193, 180-189.	0.8	15
646	Race Differences in Interventions and Survival After Outâ€ofâ€Hospital Cardiac Arrest in North Carolina, 2010 to 2014. Journal of the American Heart Association, 2021, 10, e019082.	1.6	15
647	A comparison of ionic versus nonionic contrast medium during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction (GUSTO IIb). American Journal of Cardiology, 2000, 85, 692-697.	0.7	14
648	Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: Costs of reperfusion strategies in acute myocardial infarction. American Heart Journal, 2005, 149, 637-644.	1.2	14

#	Article	IF	Citations
649	Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician. Journal of Thrombosis and Thrombolysis, 2008, 26, 167-174.	1.0	14
650	Patterns of Antihypertensive Treatment in Patients with Acute Severe Hypertension from a Nonneurologic Cause: Studying the Treatment of Acute Hypertension (STAT) Registry. Pharmacotherapy, 2010, 30, 1087-1096.	1.2	14
651	Relationship of sustained ventricular tachyarrhythmias to outcomes in patients undergoing primary percutaneous coronary intervention with varying underlying baseline risk. American Heart Journal, 2011, 161, 782-789.	1.2	14
652	Effect of Heparin Administration on Metabolomic Profiles in Samples Obtained During Cardiac Catheterization. Circulation: Cardiovascular Genetics, 2011, 4, 695-700.	5.1	14
653	Introduction to Clinical Trials. , 2015, , 1-23.		14
654	Improving Care of Out-of-Hospital Cardiac Arrest. Circulation, 2016, 134, 2040-2042.	1.6	14
655	Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease. Heart, 2018, 104, 1292-1299.	1.2	14
656	Understanding and Targeting Inflammation inÂAcute MyocardialÂInfarction. Journal of the American College of Cardiology, 2018, 72, 199-201.	1.2	14
657	Serial measurement of interleukinâ€6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and REâ€LY trials. Journal of Thrombosis and Haemostasis, 2020, 18, 2287-2295.	1.9	14
658	Preventing Atrial Fibrillation With Treatments for Diabetes Mellitus. Circulation, 2020, 141, 1235-1237.	1.6	14
659	Clinical Outcomes in Patients With ST-Segment Elevation MI and No Standard Modifiable Cardiovascular Risk Factors. JACC: Cardiovascular Interventions, 2022, 15, 1167-1175.	1.1	14
660	From signal/noise to information content/noise. Journal of Electrocardiology, 1994, 27, 233-237.	0.4	13
661	Bolus Fibrinolysis. Circulation, 2001, 103, 1171-1173.	1.6	13
662	Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Contemporary Clinical Trials, 2011, 32, 178-187.	0.8	13
663	Alcohol Withdrawal Prevention: A Randomized Evaluation of Lorazepam and Ethanol--A Pilot Study. American Journal of Critical Care, 2013, 22, 398-406.	0.8	13
664	Temporal changes in biomarkers and their relationships to reperfusion and to clinical outcomes among patients with ST segment elevation myocardial infarction. Journal of Thrombosis and Thrombolysis, 2016, 42, 376-385.	1.0	13
665	Improvement in Care and Outcomes for Emergency Medical Serviceâ€"Transported Patients With STâ€Elevation Myocardial Infarction (STEMI) With and Without Prehospital Cardiac Arrest: A Mission: Lifeline STEMI Accelerator Study. Journal of the American Heart Association, 2017, 6, .	1.6	13
666	Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial. American Heart Journal, 2018, 202, 89-96.	1.2	13

#	Article	IF	Citations
667	Association Between Driving Distance From Nearest Fire Station andÂÂSurvival of Outâ€ofâ€Hospital Cardiac Arrest. Journal of the American Heart Association, 2018, 7, e008771.	1.6	13
668	Determination of fasiglifam-induced liver toxicity: Insights from the data monitoring committee of the fasiglifam clinical trials program. Clinical Trials, 2019, 16, 253-262.	0.7	13
669	Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial. Journal of Thrombosis and Thrombolysis, 2019, 47, 345-352.	1.0	13
670	Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: Experience from GUSTO-IIb. American Heart Journal, 1999, 137, 12-23.	1.2	12
671	Lessons Learned From a Clinical Trial. Circulation, 2004, 110, 3610-3614.	1.6	12
672	Reflections on early stopping of a clinical trial. American Heart Journal, 2006, 152, 407-409.	1.2	12
673	Patient Load Effects on Response Time to Critical Arrhythmias in Cardiac Telemetry. Critical Care Medicine, 2015, 43, 1036-1042.	0.4	12
674	Rationale and design of the longâ€Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in postâ€“myocardial infarction patients (TIGRIS) study. Clinical Cardiology, 2017, 40, 1197-1204.	0.7	12
675	Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial. Open Heart, 2018, 5, e000908.	0.9	12
676	A Critical Comparison of Canadian and International Guidelines Recommendations for Antiplatelet Therapy in Coronary Artery Disease. Canadian Journal of Cardiology, 2020, 36, 1298-1307.	0.8	12
677	Pre-Hospital Antiplatelet Therapy for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: What We Know and What Lies Ahead. Thrombosis and Haemostasis, 2021, 121, 1562-1573.	1.8	12
678	Abstract 17277: Apixaban Use in Patients With Atrial Fibrillation With Bioprosthetic Valves: Insights From ARISTOTLE. Circulation, 2015, 132, .	1.6	12
679	Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention. Journal of the American College of Cardiology, 2022, 79, 417-427.	1.2	12
680	Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes. European Heart Journal, 2002, 23, 1202-1212.	1.0	11
681	An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A. Journal of Thrombosis and Thrombolysis, 2002, 14, 33-42.	1.0	11
682	Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials. European Heart Journal, 2005, 26, 128-136.	1.0	11
683	The prognostic value of the admission and predischarge electrocardiogram in acute coronary syndromes: The GUSTO-IIb ECG Core Laboratory experience. American Heart Journal, 2006, 152, 277-284.	1.2	11
684	Failure of investigator adherence to electrocardiographic entry criteria is frequent and influences clinical outcomes: lessons from APEX-AMI. European Heart Journal, 2007, 28, 2850-2857.	1.0	11

#	Article	IF	Citations
685	Usefulness of Quantitative Versus Qualitative ST-Segment Depression for Risk Stratification of Non-ST Elevation Acute Coronary Syndromes in Contemporary Clinical Practice. American Journal of Cardiology, 2008, 101, 919-924.	0.7	11
686	Integrating ancillary studies in a large clinical trial: The design and rationale of the APEX library. Contemporary Clinical Trials, 2008, 29, 887-895.	0.8	11
687	Comparison of Six-Month Outcomes for Primary Percutaneous Revascularization for Acute Myocardial Infarction With Drug-Eluting Versus Bare Metal Stents (from the APEX-AMI Study). American Journal of Cardiology, 2009, 103, 181-186.	0.7	11
688	Incidence of Thrombocytopenia among Patients Receiving Heparin Venous Thromboembolism Prophylaxis. American Journal of Medicine, 2012, 125, 1214-1221.	0.6	11
689	Critical Care Cardiology Research. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 237-242.	0.9	11
690	The cost implications of an early versus delayed invasive strategy in acute coronary syndromes: the TIMACS study. Journal of Medical Economics, 2014, 17, 415-422.	1.0	11
691	Assessing generalizability of trial results in general practice. European Heart Journal, 2016, 37, 1154-1157.	1.0	11
692	Stroke of Known Cause and Underlying Atrial Fibrillation (STROKE-AF) randomized trial: Design and rationale. American Heart Journal, 2017, 190, 19-24.	1.2	11
693	International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin. Journal of Thrombosis and Thrombolysis, 2019, 48, 27-34.	1.0	11
694	Practical challenges in the conduct of pragmatic trials embedded in health plans: Lessons of IMPACT-AFib, an FDA-Catalyst trial. Clinical Trials, 2020, 17, 360-367.	0.7	11
695	Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale. American Heart Journal, 2021, 233, 48-58.	1.2	11
696	Does 24-hour ST-segment resolution postfibrinolysis add prognostic value to a Q wave? An ASSENT 2 electrocardiographic substudy. American Heart Journal, 2003, 146, 640-645.	1.2	10
697	The impact of gender on the treatment and outcomes of patients with early reinfarction after fibrinolysis: insights from ASSENT-2â‹†. European Heart Journal, 2003, 24, 1024-1034.	1.0	10
698	Towards a new order in cardiovascular medicine: re-engineering through global collaboration. European Heart Journal, 2010, 31, 911-917.	1.0	10
699	Is visual interpretation of coronary epicardial flow reliable in patients with ST-elevation myocardial infarction undergoing primary angioplasty? Insights from the angiographic substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. American Heart Journal, 2010, 159, 899-904.	1.2	10
700	Anticoagulation, Novel Agents, and Procedures. Circulation, 2012, 126, 255-257.	1.6	10
701	Association of standard clinical and laboratory variables with red blood cell distribution width. American Heart Journal, 2016, 174, 22-28.	1.2	10
702	Apixaban to prevent stroke in patients with atrial fibrillation: a review. Therapeutic Advances in Cardiovascular Disease, 2017, 11, 91-104.	1.0	10

#	Article	IF	Citations
703	Left atrial appendage closure: A therapy uniquely suited for specific populations of patients with atrial fibrillation. Journal of Cardiovascular Electrophysiology, 2019, 30, 2968-2976.	0.8	10
704	A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2020, 96, E102-E109.	0.7	10
705	Care and outcomes of urban and non-urban out-of-hospital cardiac arrest patients during the HeartRescue Project in Washington state and North Carolina. Resuscitation, 2020, 152, 5-15.	1.3	10
706	Intracranial hemorrhage risk and new thrombolytic therapies in acute myocardial infarction. American Journal of Cardiology, 1994, 73, 444-449.	0.7	9
707	Response to Letter Regarding Article, â€œImpact of Internal Mammary Artery Conduit on Long-Term Outcomes After Percutaneous Intervention of Saphenous Vein Graftâ€. Circulation, 2006, 114, .	1.6	9
708	Impact of Internal Mammary Artery Conduit on Long-term Outcomes After Percutaneous Intervention of Saphenous Vein Graft. Circulation, 2006, 114, I-396-I-401.	1.6	9
709	Six-Month Follow-Up of Patients With In-Hospital Thrombocytopenia During Heparin-Based Anticoagulation (from the Complications After Thrombocytopenia Caused by Heparin [CATCH]) Tj ETQq1 1 0.784314 rgBT /Overlock	0.4	9
710	Dynamic modeling of 90-day mortality in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. American Heart Journal, 2013, 165, 354-362.e2.	1.2	9
711	Documentation of study medication dispensing in a prospective large randomized clinical trial: Experiences from the ARISTOTLE Trial. American Heart Journal, 2013, 166, 559-565.e1.	1.2	9
712	Prognostic implications of quantitative evaluation of baseline Q-wave width in ST-segment elevation myocardial infarction. Journal of Electrocardiology, 2014, 47, 465-471.	0.4	9
713	Use of antiarrhythmic drug therapy and clinical outcomes in older patients with concomitant atrial fibrillation and coronary artery disease. Europace, 2014, 16, 1284-1290.	0.7	9
714	Doubleâ€Ðose Versus Standardâ€Ðose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. Journal of the American Heart Association, 2017, 6, .	1.6	9
715	Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 75-81.	1.4	9
716	Peripheral blood metabolite profiles associated with new onset atrial fibrillation. American Heart Journal, 2019, 211, 54-59.	1.2	9
717	Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries. International Journal of Cardiology, 2020, 311, 7-14.	0.8	9
718	Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention. Circulation, 2021, 143, 1215-1223.	1.6	9
719	Reexamination of the Embolic Stroke of Undetermined Source Concept. Stroke, 2021, 52, 2715-2722.	1.0	9
720	Use of resources, quality of life, and clinical outcomes in patients with and without new Q waves after thrombolytic therapy for acute myocardial infarction (from the GUSTO-I trial). American Journal of Cardiology, 2000, 86, 24-29.	0.7	8

#	Article	IF	Citations
721	Pulmonary artery catheterization in patients with acute coronary syndromes. American Heart Journal, 2009, 158, 170-176.	1.2	8
722	Contribution of angiographic and electrocardiographic parameters of reperfusion to prediction of mortality and morbidity after acute ST-elevation myocardial infarction: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial. American Heart Journal, 2009, 158, 755-760.	1.2	8
723	A clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AF): design and rationale. American Heart Journal, 2016, 176, 107-113.	1.2	8
724	Temporal trends in all-cause mortality according to smoking status: Insights from the Global Registry of Acute Coronary Events. International Journal of Cardiology, 2016, 218, 291-297.	0.8	8
725	Reducing system delays in treatment of ST elevation myocardial infarction and confronting the challenges of late presentation in low and middle-income countries. Indian Heart Journal, 2017, 69, S1-S5.	0.2	8
726	Predicting risk of cardiac events among ST-segment elevation myocardial infarction patients with conservatively managed nonâ€“infarct-related artery coronary artery disease: An analysis of the Duke Databank for Cardiovascular Disease. American Heart Journal, 2017, 194, 116-124.	1.2	8
727	Confronting system barriers for ST- elevation MI in low and middle income countries with a focus on India. Indian Heart Journal, 2018, 70, 185-190.	0.2	8
728	Risk of Total Events With Icosapent Ethyl. Journal of the American College of Cardiology, 2019, 73, 2803-2805.	1.2	8
729	Stroke prevention in atrial fibrillation: Closing the gap. American Heart Journal, 2019, 210, 29-38.	1.2	8
730	Outcomes Associated with Respiratory Failure for Patients with Cardiogenic Shock and Acute Myocardial Infarction: A Substudy of the CULPRIT-SHOCK Trial. Journal of Clinical Medicine, 2020, 9, 860.	1.0	8
731	Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. Clinical Research in Cardiology, 2021, 110, 1234-1248.	1.5	8
732	Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation. Heart, 2021, 107, 713-720.	1.2	8
733	Discontinuing vs continuing ACEIs and ARBs in hospitalized patients with COVID-19 according to disease severity: Insights from the BRACE CORONA trial. American Heart Journal, 2022, 249, 86-97.	1.2	8
734	Heuristic and logistic principles of ST-segment interpretation in the time domain. Journal of Electrocardiology, 1990, 23, 6-10.	0.4	7
735	Coagulation markers and outcomes in acute coronary syndromes. American Heart Journal, 1998, 136, s7-s18.	1.2	7
736	Clinical, Electrocardiographic, and Biochemical Data for Immediate Risk Stratification in Acute Coronary Syndromes. Annals of Noninvasive Electrocardiology, 2001, 6, 64-75.	0.5	7
737	The Need for Regional Integrated Care for ST-Segment Elevation Myocardial Infarction. Circulation, 2011, 124, 851-856.	1.6	7
738	Prediction Is Very Hard, Especially About the Future. Archives of Internal Medicine, 2012, 172, 117.	4.3	7

#	Article	IF	Citations
739	Latency of ECG Displays of Hospital Telemetry Systems. Circulation, 2012, 126, 1665-1669.	1.6	7
740	Aborted myocardial infarction after primary percutaneous coronary intervention: Magnetic resonance imaging insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. American Heart Journal, 2013, 165, 226-233.	1.2	7
741	A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE. Expert Review of Cardiovascular Therapy, 2013, 11, 1105-1114.	0.6	7
742	Is there a period of liability with initiation of warfarin in patients with atrial fibrillation?. European Heart Journal, 2014, 35, 1834-1835.	1.0	7
743	Use of Oral Anticoagulation in Eligible Patients Discharged With Heart Failure and Atrial Fibrillation. Circulation: Heart Failure, 2018, 11, e005356.	1.6	7
744	Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin. Circulation, 2019, 140, 1960-1963.	1.6	7
745	Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials. American Heart Journal, 2019, 218, 110-122.	1.2	7
746	Major Adverse Cardiovascular Events After 12 Months Among Patients With Acute Coronary Syndrome Receiving Loading Doses of Atorvastatin Prior to Planned PCI. JAMA - Journal of the American Medical Association, 2020, 323, 787.	3.8	7
747	Risk markers of incident atrial fibrillation in patients with coronary heart disease. American Heart Journal, 2021, 233, 92-101.	1.2	7
748	Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. Open Heart, 2021, 8, e001471.	0.9	7
749	Health Systemâ€“Level Performance in Prescribing Guideline-Directed Medical Therapy for Patients with HFrEF: Results from the CONNECT-HF Trial. Journal of Cardiac Failure, 2022, , .	0.7	7
750	Platelet Function and Fibrinolytic Agents: Two Sides of a Coin?. Cardiology, 2001, 95, 55-60.	0.6	6
751	Development and validation of a simple model to predict severe coronary artery disease after myocardial infarction: Potential impact on cardiac catheterization use in the United States and Canada. American Heart Journal, 2003, 145, 349-355.	1.2	6
752	Relation Between Previous Lipid-Lowering Therapy and Infarct Size (Creatine Kinase-MB Level) in Patients Presenting With Acute Myocardial Infarction. American Journal of Cardiology, 2008, 102, 1119-1124.	0.7	6
753	Antiplatelet and Anticoagulant Therapy for Stroke Prevention in Patients With Non-Valvular Atrial Fibrillation: Evidence Based Strategies and New Developments. Revista Espanola De Cardiologia (English Ed), 2011, 64, 260-268.	0.4	6
754	Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) trial. American Heart Journal, 2012, 163, 797-803.	1.2	6
755	The King is Dead (Warfarin): Direct Thrombin and Factor Xa Inhibitors: The Next Diadochian War?. International Journal of Stroke, 2012, 7, 139-141.	2.9	6
756	Atrial Fibrillation: A Review of Recent Studies with a Focus on Those from the Duke Clinical Research Institute. Scientifica, 2014, 2014, 1-11.	0.6	6

#	Article	IF	Citations
757	Idarucizumab since FDA approval: Use in the real-world. American Heart Journal, 2017, 193, 93-94.	1.2	6
758	Interruption of non-vitamin K antagonist anticoagulants in patients undergoing planned invasive procedures: how long is long enough?. European Heart Journal, 2017, 38, 2440-2443.	1.0	6
759	High-throughput targeted proteomics discovery approach and spontaneous reperfusion in ST-segment elevation myocardial infarction. American Heart Journal, 2020, 220, 137-144.	1.2	6
760	Heart Failure Clinical Trial Operations During the COVID-19 Pandemic. Circulation: Heart Failure, 2020, 13, e007456.	1.6	6
761	Association of Different Estimates of Renal Function With Cardiovascular Mortality and Bleeding in Atrial Fibrillation. Journal of the American Heart Association, 2020, 9, e017155.	1.6	6
762	Catheterization Laboratory Activation Time in Patients Transferred With ST-Segmentâ€“Elevation Myocardial Infarction: Insights From the Mission: Lifeline STEMI Accelerator-2 Project. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006204.	0.9	6
763	Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 227-235.	1.4	6
764	Novel multi-marker proteomics in phenotypically matched patients with ST-segment myocardial infarction: association with clinical outcomes. Journal of Thrombosis and Thrombolysis, 2021, , 1.	1.0	6
765	Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model. American Heart Journal, 2022, 251, 13-24.	1.2	6
766	Platelets and Thrombolysis: Cooperation or Contrariety?. Cardiology, 2001, 1, 281-290.	0.3	5
767	ST Resolution 1 Hour After Fibrinolysis for Prediction of Myocardial Infarct Size: Insights from ASSENT 3. American Journal of Cardiology, 2009, 103, 154-158.	0.7	5
768	Prediction of enzymatic infarct size in ST-segment elevation myocardial infarction. Coronary Artery Disease, 2012, 23, 118-125.	0.3	5
769	Management and outcomes of patients presenting with STEMI by use of chronic oral anticoagulation: results from the GRACE registry. European Heart Journal: Acute Cardiovascular Care, 2013, 2, 280-291.	0.4	5
770	Should patients on vitamin K antagonists be treated differently?. European Heart Journal, 2015, 36, 1431-1433.	1.0	5
771	Out-of-Hospital Cardiac Arrest. JACC: Cardiovascular Interventions, 2017, 10, 460-461.	1.1	5
772	Regional differences in presentation and antithrombotic treatment of patients with atrial fibrillation: Baseline characteristics from a clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with atrial fibrillation (IMPACT-AF). American Heart Journal, 2017, 192, 38-47.	1.2	5
773	Patterns of use of targeted temperature management for acute myocardial infarction patients following out-of-hospital cardiac arrest: Insights from the National Cardiovascular Data Registry. American Heart Journal, 2018, 206, 131-133.	1.2	5
774	Regional variation in clinical characteristics and outcomes in patients with atrial fibrillation: Findings from the ARISTOTLE trial. International Journal of Cardiology, 2020, 302, 53-58.	0.8	5

#	Article	IF	Citations
775	Evaluation of the Age, Biomarkers, and Clinical Historyâ€“Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials. JAMA Network Open, 2020, 3, e2015943.	2.8	5
776	Implementation of Best Practicesâ€”Developing and Optimizing Regional Systems of Stroke Care: Design and Methodology. American Heart Journal, 2020, 222, 105-111.	1.2	5
777	In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c <â€7% are associated with lower major cardiovascular events. American Heart Journal, 2020, 225, 97-107.	1.2	5
778	Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials. JAMA Network Open, 2021, 4, e2117963.	2.8	5
779	Data Collection and Quality Control. , 2015, , 233-253.		5
780	Multicenter Trials. , 2015, , 501-518.		5
781	Pexelizumab: A novel therapy for mycardial ischemia-reperfusion. Drugs of Today, 2005, 41, 165.	2.4	5
782	Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarction. Open Heart, 2021, 8, e001726.	0.9	5
783	OUP accepted manuscript. European Heart Journal: Acute Cardiovascular Care, 2022, , .	0.4	5
784	Predictors of Recurrent Stroke After Embolic Stroke of Undetermined Source in the REâ€SPECT ESUS Trial. Journal of the American Heart Association, 2022, 11, .	1.6	5
785	Predictors of outcome of reperfusion therapy. European Heart Journal, 1997, 18, 728-735.	1.0	4
786	Outcomes of diabetic patients following acute myocardial infarction: a review of the major thrombolytic trials. European Journal of Cardiovascular Prevention and Rehabilitation, 1997, 4, 100-111.	1.5	4
787	The CHARM programme. Lancet, The, 2003, 362, 1678-1679.	6.3	4
788	Integrating antithrombin and antiplatelet therapies with early invasive management for nonâ€“ST-segment elevation acute coronary syndromes. American Journal of Medicine, 2004, 116, 119-129.	0.6	4
789	Timing of Death and Myocardial Infarction in Patients with Non-ST Elevation Acute Coronary Syndromes: Insights From Randomized Clinical Trials. Journal of Interventional Cardiology, 2007, 20, 299-306.	0.5	4
790	Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis. European Heart Journal, 2009, 30, 2213-2219.	1.0	4
791	Contribution of Bleeding and Thromboembolic Events to In-Hospital Mortality Among Patients With Thrombocytopenia Treated With Heparin. American Journal of Cardiology, 2009, 104, 292-297.	0.7	4
792	STREAMlining care for patients with STEMI. Nature Reviews Cardiology, 2013, 10, 304-306.	6.1	4

#	Article	IF	Citations
793	Improving Integrated Care in Lowâ€•and Middleâ€Income Countries: The Final STEMI Frontier?. Journal of Interventional Cardiology, 2014, 27, 167-170.	0.5	4
794	Warfarin use and long-term outcomes in patients with acute myocardial infarction and atrial fibrillation. Journal of Thrombosis and Thrombolysis, 2014, 37, 331-337.	1.0	4
795	Rationale and design of the Statins Evaluation in Coronary procedUres and REvascularization: The SECURE-PCI Trial. American Heart Journal, 2018, 198, 129-134.	1.2	4
796	Effects of apixaban compared with warfarin as gain in event-free time â€“ a novel assessment of the results of the ARISTOTLE trial. European Journal of Preventive Cardiology, 2020, 27, 1311-1319.	0.8	4
797	Novel Biomarkers, STâ€Elevation Resolution, and Clinical Outcomes Following Primary Percutaneous Coronary Intervention. Journal of the American Heart Association, 2020, 9, e016033.	1.6	4
798	A reversal of fortune: A case of cardiovascular collapse following protamine sulfate infusion. HeartRhythm Case Reports, 2020, 6, 322-324.	0.2	4
799	Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: Insights from the TREAT trial. American Heart Journal, 2022, 251, 1-12.	1.2	4
800	Effect of Mailing Educational Material to Patients With Atrial Fibrillation and Their Clinicians on Use of Oral Anticoagulants. JAMA Network Open, 2022, 5, e2214321.	2.8	4
801	Lessons learned in the Apple Heart Study and implications for the data management of future digital clinical trials. Journal of Biopharmaceutical Statistics, 0, , 1-15.	0.4	4
802	Augmentation of mortality risk discriminating power of left ventricular ejection fraction by measures of nonuniformity in systolic emptying on radionuclide ventriculography. Journal of the American College of Cardiology, 1990, 16, 387-395.	1.2	3
803	Diet and secondary prevention of coronary disease: Is it time to stop chewing the fat?. Journal of the American College of Cardiology, 1996, 28, 1109-1110.	1.2	3
804	Outcomes of Diabetic Patients Following Acute Myocardial Infarction: A Review of the Major Thrombolytic Trials. European Journal of Cardiovascular Prevention and Rehabilitation, 1997, 4, 100-111.	3.1	3
805	Physicians' Use of Heparin Following Thrombolytic Therapy: An International Perspective. Journal of Thrombosis and Thrombolysis, 1997, 4, 415-423.	1.0	3
806	The use of tomographic myocardial perfusion scanning to evaluate an electrocardiographic salvage estimation method in patients with acute myocardial infarction: An AMISTAD substudy. Journal of Electrocardiology, 1999, 32, 111-113.	0.4	3
807	Variation in the use of stress testing and outcomes in patients with non-ST-elevation acute coronary syndromes: insights from GUSTO IIb. European Heart Journal, 2008, 29, 880-887.	1.0	3
808	Advancing care for acute heart failureâ€”no time to relax. Lancet, The, 2009, 373, 1401-1402.	6.3	3
809	Who should have a routine early invasive approach after fibrinolytic therapy?. European Heart Journal, 2011, 32, 1961-1963.	1.0	3
810	ST-Segmentâ€“Elevation Myocardial Infarction Treatment and the Seductive Lure of Observational Analyses. Circulation, 2011, 124, 2477-2479.	1.6	3

#	Article	IF	Citations
811	Review: Statins reduce mortality and cardiovascular (CV) morbidity in patients with low CV risk. Annals of Internal Medicine, 2012, 156, JC4.	2.0	3
812	Promise of Factor Xa Inhibition in Atrial Fibrillation. Current Cardiology Reports, 2012, 14, 70-78.	1.3	3
813	Corrigendum to â€˜Analysing recurrent hospitalizations in heart failure: a review ofÂstatistical methodology, with application toÂCHARM-Preservedâ€™ [Eur J Heart Fail2014;16:33-40]. European Journal of Heart Failure, 2014, 16, 592-592.	2.9	3
814	Roger et al. Respond to "Future of Population Studies". American Journal of Epidemiology, 2015, 181, 372-373.	1.6	3
815	Intracerebral haemorrhage, atrial fibrillation, and anticoagulation â€“ Authors' reply. Lancet, The, 2015, 386, 1737.	6.3	3
816	Implementation of Regional ST-Segment Elevation Myocardial Infarction Systems of Care. Interventional Cardiology Clinics, 2016, 5, 415-425.	0.2	3
817	Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect. Cardiovascular Drugs and Therapy, 2017, 31, 295-301.	1.3	3
818	Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trial. International Journal of Cardiology, 2017, 227, 443-449.	0.8	3
819	Discharge timing and outcomes after uncomplicated nonâ€“ST-segment elevation acute myocardial infarction. American Heart Journal, 2018, 201, 103-110.	1.2	3
820	Diabetes association with selfâ€reported health, resource utilization, and prognosis postâ€myocardial infarction. Clinical Cardiology, 2020, 43, 1352-1361.	0.7	3
821	Managing patients with ST-elevation myocardial infarction and multivessel disease: is the story complete?. European Heart Journal, 2020, 41, 4111-4113.	1.0	3
822	The SAMSON trial: using a placebo to improve medication tolerability. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e13-e13.	1.4	3
823	Assessment and Reporting of Harm. , 2015, , 255-277.		3
824	Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke. JAMA Cardiology, 2022, 7, 682.	3.0	3
825	908-109 Incremental Prognostic Value of Electrocardiographic Findings when Added to Baseline Clinical Variables in Patients with Acute Myocardial Infarction. Journal of the American College of Cardiology, 1995, 25, 60A.	1.2	2
826	Noninvasive testing is done only in low risk patients with unstable angina and non-Q-wave Myocardial Infarction (MI): Results from GUSTO-IIa. Journal of the American College of Cardiology, 1996, 27, 181-182.	1.2	2
827	Does the presence or absence of chest pain at initiation of thrombolysis in acute myocardial infarction affect outcome?. Journal of the American College of Cardiology, 1996, 27, 389.	1.2	2
828	Heparin management in acute myocardial infarction (AMI). Australian and New Zealand Journal of Medicine, 1998, 28, 541-547.	0.5	2

#	Article	IF	Citations
829	Genetics in heart failure: Practical incorporation of this new biologic dimension. American Heart Journal, 2002, 144, 938-940.	1.2	2
830	The Editor's Roundtable: Arterial Thrombosis and Acute Coronary Syndromes. American Journal of Cardiology, 2007, 100, 974-980.	0.7	2
831	Treatment Strategies in Nonâ€STâ€Elevation Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary Intervention: An Evidenceâ€Based Review of Clinical Trial Results and Treatment Guidelines: Report on a Roundtable Discussion. Journal of Interventional Cardiology, 2008, 21, 283-299.	0.5	2
832	The Editor's Roundtable: Management and Treatment of Non-ST-Segment Elevation in Acute Coronary Syndromes. American Journal of Cardiology, 2008, 101, 1580-1598.	0.7	2
833	Highlights from the I international symposium of thrombosis and anticoagulation in internal medicine, October 23â€“25, 2008, Sao Paulo, Brazil. Journal of Thrombosis and Thrombolysis, 2009, 28, 106-116.	1.0	2
834	Expert consensus on treatment strategies in nonâ€“ST-segment elevation acute coronary syndromes in patients undergoing percutaneous coronary interventionâ€”an evidence-based review of clinical trial results and treatment guidelines from an emergency medicine perspective: report on a roundtable discussion. American Journal of Emergency Medicine, 2009, 27, 720-728.	0.7	2
835	Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14â€“16, 2010, SÃ£o Paulo, Brazil. Journal of Thrombosis and Thrombolysis, 2011, 32, 242-266.	1.0	2
836	Treatment Pathways and Quality Improvement for Patients With Acute Myocardial Infarction at a Tertiary Care Center. Critical Pathways in Cardiology, 2012, 11, 77-80.	0.2	2
837	Prognostic Impact of an Ischemic Etiology of Chronic Heart Failure across the Spectrum of Ejection Fractions in the CHARM Program. Journal of Cardiac Failure, 2012, 18, S78.	0.7	2
838	Cardiovascular clinical research in South America. American Heart Journal, 2013, 165, 848-853.	1.2	2
839	Left Bundle Branch Block in Nonâ€“ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology, 2013, 61, 1461-1463.	1.2	2
840	Regional systems of care for ST-elevation myocardial infarction: Do they save lives?. American Heart Journal, 2013, 166, 389-391.	1.2	2
841	Randomized Clinical Trial Progress to Inform Care for Out-of-Hospital Cardiac Arrest. JAMA - Journal of the American Medical Association, 2014, 311, 31.	3.8	2
842	Assessing Oral Beta-BlockerÂTherapy After Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2014, 7, 602-603.	1.1	2
843	Therapeutic Hypothermia for Patients with Out-of-Hospital Cardiac Arrest in North Carolina. Prehospital Emergency Care, 2016, 20, 630-636.	1.0	2
844	Insulin Therapy and Stroke Risk in Patients With Diabetes and Atrial Fibrillation. Journal of the American College of Cardiology, 2017, 69, 420-422.	1.2	2
845	Q Waves at Presentation in Patients With ST-Segmentâ€“Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	2
846	Improving Evidence for Implementation of Guideline-Based Care in Low- and Middle-Income Countries. JAMA - Journal of the American Medical Association, 2018, 319, 554.	3.8	2

#	Article	IF	Citations
847	Continuous anticoagulation with catheter ablation: answers and questions. European Heart Journal, 2019, 40, 3022-3025.	1.0	2
848	Predicting outcome in cardiac arrest: some progress, but more work needed. European Heart Journal, 2020, 41, 4518-4520.	1.0	2
849	Abstract 16741: The Cost-Effectiveness of Apixaban versus Warfarin in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Study Group. Circulation, 2014, 130, .	1.6	2
850	Recruitment of Study Participants. , 2015, , 215-232.		2
851	Assessing the effect of publication of clinical guidelines on the management of unstable angina and non-ST elevation myocardial infarction in the TIMI III (1990-1993) and the GUARANTEE (1995-1996) Registries. Critical Pathways in Cardiology, 2002, 1, 150-8.	0.2	2
852	Evidence Builds for Catheter Ablation for Atrial Fibrillation and Heart Failure. Circulation, 2022, 145, 1705-1707.	1.6	2
853	755-6 Neurosurgical Evacuation for Intracranial Hemorrhage Associated with Improved Outcome in GUSTO. Journal of the American College of Cardiology, 1995, 25, 232A-233A.	1.2	1
854	P71 Impact of the clinical events committee process on data safety monitoring. Contemporary Clinical Trials, 1996, 17, S135.	2.0	1
855	The GUSTO Trials. Journal of Interventional Cardiology, 1999, 12, 13-31.	0.5	1
856	"Hot" unstable angina--is it worse than subacute unstable angina? Results from the GUARANTEE Registry. Journal of Thrombosis and Thrombolysis, 2001, 12, 207-216.	1.0	1
857	Assessing the Effect of Publication of Clinical Guidelines on the Management of Unstable Angina and Non-ST Elevation Myocardial Infarction in The TIMI III (1990-1993) and the GUARANTEE (1995-1996) Registries. Critical Pathways in Cardiology, 2002, 1, 150-158.	0.2	1
858	Association of Height With Outcomes in Patients With Acute Myocardial Infarction Receiving Reperfusion Therapy. American Journal of Cardiology, 2005, 95, 1371-1375.	0.7	1
859	Response to Letter Regarding Article, â€œInfluence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failureâ€• Circulation, 2008, 118, .	1.6	1
860	Dual Renin-Angiotensin System Blockade in Heart Failure. Journal of the American College of Cardiology, 2009, 54, 278.	1.2	1
861	Biomarkers in Stroke. Journal of the American College of Cardiology, 2010, 56, 1054-1055.	1.2	1
862	Novel Oral Anticoagulants After Acute Coronary Syndromes. Cardiovascular Drugs and Therapy, 2012, 26, 265-271.	1.3	1
863	A 10-year exercise program improved oxygen consumption and quality of life in stable chronic heart failure. Annals of Internal Medicine, 2013, 158, JC2.	2.0	1
864	Response to Letter Regarding Article, â€œEfficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillationâ€• Circulation, 2014, 129, e21-2.	1.6	1

#	Article	IF	Citations
865	Another Biomarker for Risk Assessment in Acute Myocardial Infarction?âˆ—. Journal of the American College of Cardiology, 2014, 64, 1708-1710.	1.2	1
866	Practical advice on safe and effective use of non-vitamin K antagonist oral anticoagulants. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 146-147.	1.4	1
867	Potential Relief for Refractory Angina. New England Journal of Medicine, 2015, 372, 566-567.	13.9	1
868	Stroke Prediction in Atrial Fibrillation. Journal of the American College of Cardiology, 2016, 68, 471-472.	1.2	1
869	More Evidence That Caffeine Consumption Appears to Be Safe in Patients With Heart Failure. JAMA Internal Medicine, 2016, 176, 1759.	2.6	1
870	Reduction of ischemic events in Improved Reduction of Outcomes: Vytorin Efficacy International Trial: Intensive cholesterol lowering or ezetimibe antithrombotic effects?. American Heart Journal, 2016, 172, 42-44.	1.2	1
871	Traumatic injury: another unjustified reason to stop oral anticoagulation for atrial fibrillation. European Heart Journal, 2018, 39, 1706-1708.	1.0	1
872	Anticoagulation Drug Trials for Stroke Prevention in Atrial Fibrillation. , 2019, , 35-46.		1
873	The changing epidemiology of ventricular arrhythmias and sudden cardiac death: Is it a reality?. Heart Rhythm, 2019, 16, 367-368.	0.3	1
874	In ACS, ticagrelor and prasugrel each reduce some ischemic events but increase major bleeding vs. clopidogrel. Annals of Internal Medicine, 2020, 173, JC44.	2.0	1
875	In patients with recent ACS and uncontrolled dyslipidemia, alirocumab reduced MACE regardless of previous CABG. Annals of Internal Medicine, 2020, 172, JC3.	2.0	1
876	Influence of Clinical Trials of Acute Coronary Syndrome Beyond the Primary Hypothesis. JAMA Cardiology, 2020, 5, 1286.	3.0	1
877	Warfarin for Atrial Fibrillation Stroke Prophylaxis in Advanced Kidney Disease. JACC: Clinical Electrophysiology, 2020, 6, 1669-1671.	1.3	1
878	Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009614.	2.1	1
879	AORTIC VALVE ENDOCARDITIS AS A COMPLICATION OF TOCILIZUMAB TREATMENT IN COVID 19 PATIENT. Journal of the American College of Cardiology, 2021, 77, 3002.	1.2	1
880	What Is the Question?. , 2015, , 49-71.		1
881	Impact of different patterns of invasive care on quality of life outcomes in patients with non-ST elevation acute coronary syndrome: results from the GUSTO-IIb Canada-United States substudy. Canadian Journal of Cardiology, 2004, 20, 760-6.	0.8	1
882	Personalizing Choice of CABG vs PCI for Multivessel Disease. Journal of the American College of Cardiology, 2022, 79, 1474-1476.	1.2	1

#	Article	IF	Citations
883	Acute ischemic heart disease. American Heart Journal, 2000, 139, S189-S192.	1.2	0
884	Recommendations for national and local regulatory authorities concerning research in genetic markers of disease. American Heart Journal, 2000, 140, S3-S5.	1.2	0
885	Assessing the Effect of Publication of Clinical Guidelines on the Management of Unstable Angina and Non-ST Elevation Myocardial Infarction in The TIMI III (1990???1993) and the GUARANTEE (1995???1996) Registries. Critical Pathways in Cardiology, 2002, 1, 150-158.	0.2	0
886	Reduction in all-cause mortality and morbidity with candesartan in patients with chronic heart failure and systolic left ventricular dysfunction: results of the CHARM low EF trials. Journal of Cardiac Failure, 2004, 10, S76.	0.7	0
887	Importance of CHARM in relation to other heart failure trials with ARBs. European Heart Journal Supplements, 2004, 6, h55-h60.	0.0	0
888	Noncardiac Surgery: Evaluating and Minimizing Cardiac Risk. Current Cardiology Reviews, 2005, 1, 71-79.	0.6	0
889	Glucose, insulin, and acute myocardial infarction: reply. European Heart Journal, 2006, 27, 2142-2143.	1.0	0
890	Carvedilol was more effective than metoprolol for preventing cardiovascular events in heart failure. Evidence-Based Medicine, 2007, 12, 141-141.	0.6	0
891	Anticoagulant Agents. Fundamental and Clinical Cardiology, 2008, , 195-232.	0.0	0
892	Review: an early invasive strategy has similar benefits in men and women with NSTEMI or unstable angina. Evidence-Based Medicine, 2009, 14, 19-19.	0.6	0
893	Economic Assessment of Thrombocytopenia: CATCH Registry. Journal of Medical Systems, 2010, 34, 379-386.	2.2	0
894	Interpreting the TRITON Results in Light of the Event Adjudication Process. Cardiology, 2010, 115, 89-90.	0.6	0
895	No difference in peak troponin level in immediate versus delayed (next working day) intervention for acute coronary syndrome without ST-segment elevation. Evidence-Based Medicine, 2010, 15, 26-27.	0.6	0
896	Review: Reduced function CYP2C19 genotypes may increase risk for stent clots in patients receiving clopidogrel. Annals of Internal Medicine, 2011, 155, JC6.	2.0	0
897	Response to Letter Regarding Article, â€œAcute Kidney Injury and Cardiovascular Outcomes in Acute Severe Hypertensionâ€• Circulation, 2011, 123, .	1.6	0
898	Challenging accepted post-MI serum potassium targets. Nature Reviews Cardiology, 2012, 9, 259-260.	6.1	0
899	Letter by Van de Werf et al Regarding Article, â€œUsing Dabigatran in Patients With Stroke: A Practical Guide for Cliniciansâ€• Stroke, 2012, 43, e46-7; author reply e49.	1.0	0
900	263 The Forgotten Lead: Does aVR ST-Deviation Add Insight Into STEMI Patients?. Canadian Journal of Cardiology, 2012, 28, S189-S190.	0.8	0

#	Article	IF	Citations
901	Regionalization of ST-segment elevation myocardial infarction care: A task unfinished. American Heart Journal, 2012, 164, 633-635.	1.2	0
902	TCT-64 Bypassing The Emergency Department Is Associated With Faster Reperfusion In Patients With Pre-Hospital ST-Segment Elevation: Findings From The Reperfusion Of Acute Myocardial Infarction In Carolina Emergency Departments (RACE) Project. Journal of the American College of Cardiology, 2012, 60, B20.	1.2	0
903	Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20â€“21, 2011, Salvador, Bahia, Brazil. Journal of Thrombosis and Thrombolysis, 2012, 34, 143-163.	1.0	0
904	Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), october 18â€“19, 2012, Belo Horizonte, Minas Gerais, Brazil. Journal of Thrombosis and Thrombolysis, 2013, 36, 115-130.	1.0	0
905	Response to letter â€œAssociations of inflammatory biomarkers to body mass index among patients with acute coronary syndromeâ€• International Journal of Cardiology, 2013, 168, 4543.	0.8	0
906	Applying Antithrombotic Therapies to Improve Outcomes in Patients With Atrial Fibrillation. American Journal of Cardiology, 2013, 112, S3.	0.7	0
907	Reply. Journal of the American College of Cardiology, 2013, 62, 1635-1636.	1.2	0
908	The Reply. American Journal of Medicine, 2013, 126, e21.	0.6	0
909	Learning from regional heterogeneity in outcomes of patients with acute myocardial infarction. European Heart Journal, 2013, 34, 3171-3172.	1.0	0
910	Systems of Health Care. , 2013, , 67-74.		0
911	Board 538 - Technology Innovations Abstract Simulating Remote Cardiac Telemetry Monitoring (Submission #1001). Simulation in Healthcare, 2013, 8, 628.	0.7	0
912	Response to Letter Regarding Article, â€œEmergency Department Bypass for ST-Segmentâ€“Elevation Myocardial Infarction Patients Identified With a Prehospital Electrocardiogram: A Report From the American Heart Association Mission: Lifeline Programâ€• Circulation, 2014, 129, e372.	1.6	0
913	Adding ezetimibe to simvastatin improved cardiovascular outcomes in stable acute coronary syndrome. Annals of Internal Medicine, 2015, 163, JC7.	2.0	0
914	EARLY DEFIBRILLATION BY FIRST-RESPONDERS IN RELATION TO FIRE STATIONS: OPTIMAL BENEFIT ACCORDING TO LOCATION. Journal of the American College of Cardiology, 2017, 69, 2486.	1.2	0
915	ACCELERATOR 2 SUSTAIN, A U.S. REGIONAL SYSTEMS OF CARE DEMONSTRATION PROJECT FOR POST-DISCHARGE STEMI PATIENTS: PRELIMINARY DATA, METHODS AND DESIGN. Journal of the American College of Cardiology, 2017, 69, 2500.	1.2	0
916	Guideline: The USPSTF recommends low- to moderate-dose statins to prevent CVD in selected adults 40 to 75 years of age. Annals of Internal Medicine, 2017, 166, JC26.	2.0	0
917	Review: A single hs-cTnT with a cutpoint < limit of detection plus a nonischemic ECG can rule out acute MI. Annals of Internal Medicine, 2017, 167, JC23.	2.0	0
918	In patients with chest pain, HEART Pathwayâ€“guided and usual care did not differ for MACE or health care use. Annals of Internal Medicine, 2018, 169, JC69.	2.0	0

#	Article	IF	Citations
919	Sodium bicarb vs sodium chloride, and acetylcysteine vs placebo, did not differ for adverse events after angiography. Annals of Internal Medicine, 2018, 168, JC22.	2.0	0
920	TRANSFUSIONS, WITH OR WITHOUT CONCOMITANT BLEEDING, ARE ASSOCIATED WITH HIGH SHORT-TERM MORTALITY IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH ORAL ANTICOAGULATION. Journal of the American College of Cardiology, 2019, 73, 399.	1.2	0
921	Reply. JACC: Cardiovascular Interventions, 2019, 12, 107.	1.1	0
922	TCT-160 Impact of White Blood Cell Count on Infarct Size and Clinical Outcomes Following Primary PCI: Patient-Level Analysis From 6 Randomized Trials. Journal of the American College of Cardiology, 2019, 74, B159.	1.2	0
923	USE OF EVIDENCE-BASED PREVENTIVE MEDICAL THERAPIES 1-3 YEARS POST-MYOCARDIAL INFARCTION IN THE PROSPECTIVE GLOBAL TIGRIS REGISTRY. Journal of the American College of Cardiology, 2019, 73, 169.	1.2	0
924	Authorsâ€™ Reply. Journal of the American Society of Nephrology: JASN, 2019, 30, 1137-1138.	3.0	0
925	In middle-aged adults, Astro-CHARM was better than a standard risk factor model for predicting 10-year ASCVD risk. Annals of Internal Medicine, 2019, 170, JC23.	2.0	0
926	4031 Heart Transplant Candidates Listed at Low First-Offer Organ Acceptance Rate Centers are More Likely to Die Waiting. Journal of Clinical and Translational Science, 2020, 4, 133-134.	0.3	0
927	Standardizing ST-Segment Elevation Myocardial Infarction Care. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007701.	0.9	0
928	LOW-HARM score predicted mortality in patients hospitalized with COVID-19 in Mexico. Annals of Internal Medicine, 2021, 174, JC59.	2.0	0
929	Predictors of death and reinfarction at 30 days after primary angioplasty: The GUSTO IIb and RAPPORT trials. American Heart Journal, 2000, 139, 0476-0481.	1.2	0
930	2704 Understanding time to treatment in acute myocardial infarction: insights from ASSENT 3 plus. European Heart Journal, 2003, 24, 502.	1.0	0
931	In patients with suspected CAD and normal ECG, a nomogram model based on clinical and exercise variables predicted mortality. Annals of Internal Medicine, 2008, 148, JC4.	2.0	0
932	The Modern Cardiac Care Unit. , 2011, , 405-416.		0
933	Inflammation and Immunity as Targets for Drug Therapy in Acute Coronary Syndrome. , 2011, , 271-288.		0
934	Current Approaches to Prevention and Management of Reperfusion Injury. , 2012, , 215-238.		0
935	The GUSTO-I Trial. Developments in Cardiovascular Medicine, 1994, , 135-148.	0.1	0
936	Participant Adherence. , 2015, , 297-318.		0

#	Article	IF	Citations
937	Closeout. , 2015, , 463-477.		0
938	Abstract 17205: Polypharmacy and the Impact of Apixaban on Clinical Events in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial. Circulation, 2015, 132, .	1.6	0
939	Abstract 16755: Association Between Achievement of Risk Factor Standard of Care Goals and Major Adverse Cardiovascular Events in Patients With Stable Coronary Artery Disease in the STABILITY Trial. Circulation, 2015, 132, .	1.6	0
940	Abstract 12404: Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Normal Renal Function over Time: Insights From the ARISTOTLE Trial. Circulation, 2015, 132, .	1.6	0
941	A nomogram of exercise capacity for age predicted mortality in women with cardiovascular symptoms. ACP Journal Club, 2006, 144, 25.	0.1	0
942	Abstract 17083: SARS-CoV-2 Dramatically Decreases Healthcare Access for Patients With Cardiovascular Disease. Circulation, 2020, 142, .	1.6	0
943	Progress in regional systems of care for STEMI in low- and middle-income countries. AsiaIntervention, 2021, 7, 11-14.	0.1	0
944	Reducing cardiac events after acute coronary syndromes. Reviews in Cardiovascular Medicine, 2004, 5 Suppl 5, S39-46.	0.5	0
945	Trandolapril did not reduce cardiovascular death or other events in stable coronary artery disease. ACP Journal Club, 2005, 142, 66.	0.1	0
946	A nomogram of exercise capacity for age predicted mortality in women with cardiovascular symptoms. ACP Journal Club, 2006, 144, 25.	0.1	0
947	Bleeding in acute coronary syndromes. Timely Topics in Medicine Cardiovascular Diseases [electronic Resource], 2006, 10, E30.	0.1	0
948	Review: Angiotensin II receptor blocker plus angiotensin-converting enzyme inhibitor increases risk for adverse effects. ACP Journal Club, 2008, 148, 35.	0.1	0
949	Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial. Open Heart, 2022, 9, e001892.	0.9	0
950	Efficacy and Safety of Antithrombotic Therapy in Patients With Atrial Fibrillation, Recent Acute Coronary Syndrome, or Percutaneous Coronary Intervention and a History of Heart Failure: Insights From the AUGUSTUS Trial. Journal of the American Heart Association, 2021, 10, e023143.	1.6	0
951	CE-543-01 4-FOLD HIGHER RATE OF ATRIAL FIBRILLATION DETECTION AFTER STROKE OF PRESUMED KNOWN ETIOLOGY WITH CONTINUOUS VERSUS INTERMITTENT MONITORING: RESULTS FROM THE STROKE AF STUDY. Heart Rhythm, 2022, 19, S85.	0.3	0
952	Trandolapril did not reduce cardiovascular death or other events in stable coronary artery disease. ACP Journal Club, 2005, 142, 66.	0.1	0
953	A risk stratification tool predicted in-hospital mortality in acute decompensated heart failure. ACP Journal Club, 2005, 143, 25.	0.1	0
954	Abstract 17236: Intracranial Hemorrhage in Patients With Atrial Fibrillation in the ARISTOTLE Trial: Clinical Characteristics and Associated Outcomes. Circulation, 2015, 132, .	1.6	0

#	Article	IF	Citations
955	Abstract 17437: Do Patients With Uncomplicated Non-ST Segment Acute Coronary Syndromes Require Admission to Critical Care Units?. Circulation, 2015, 132, .	1.6	0